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ABSTRACT 
The APOBEC3 (Apo3) family of proteins are single stranded (ss) DNA cytosine 
deaminases (C → U).  They are grouped into two different structural groups, the single catalytic 
domain Apo3 enzymes (Apo3A, Apo3C, and Apo3H) and the double catalytic domain Apo3 
enzymes (Apo3B, Apo3D, Apo3F, and Apo3G).  Apo3G has been implicated in protection from 
HIV proliferation by becoming encapsidated into budding HIV virions and subsequently 
mutationally inactivating the synthesized provirus.  This largely occurs in the absence of HIV 
viral infectivity factor (Vif) which mediates the ubiquitination and degradation of Apo3G.  
Apo3G is a processive enzyme, able to catalyze numerous deaminations in a 5'CCC motif in a 
single interaction with a substrate.  There is a paucity of biochemical data on other Apo3 family 
members.  We performed basic biochemical assays that determined the relative specific 
activities, processivity, cytosine motif preferences, and binding affinities for DNA, of Apo3A 
and Apo3H using synthetic DNA substrates in deamination assays.  We found Apo3A to be an 
enzyme with low processivity and Apo3H to be a highly processive enzyme; both of which 
deaminate a 5'TC motif.  Using a reconstituted HIV replication assay we assessed if processivity 
is needed for efficient restriction of HIV.  We were able to demonstrate that each, Apo3G, 
Apo3A, and Apo3H were able to catalyze deaminations during in vitro reverse transcription.  
The mutation profile of both Apo3A and Apo3H showed that the 5'TC motif preference was less 
effective compared to Apo3G in triggering missense and nonsense mutations in the HIV protease 
active site coding sequence. 
Nuclear DNA can become deaminated by the related Apo3 family member activation-
induced deaminase (AID), when it is present in the nucleus of activated B cells.  Apo3A and 
Apo3H are located in the nucleus but the extent of the damage they cause has only recently been 
investigated.  Here we used an in vitro transcription assay to determine the efficiency of Apo3A 
and Apo3H deamination during transcription and found that, like AID, they are highly capable of 
causing deaminations during transcription. 
Taken together, the results presented here demonstrate that processivity is not necessary 
for an Apo3 enzyme to catalyze deaminations during HIV reverse transcription and that Apo3A 
and Apo3H can catalyze deaminations during DNA transcription that could damage host 
genomic DNA.  These results imply a potential cost for maintaining nuclear deaminases.  
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INTRODUCTION  
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1.1 Overview 
Human cells contain a retroelement restriction system consisting of the cytosine 
deaminases from the APOBEC3 family.  These enzymes work by deaminating cytosine to uracil 
in single stranded (ss)DNA which results in C→T or other types of mutations during replication 
of the deaminated DNA.  This can be a defense against retroelements by causing their mutational 
inactivation.  Retroelement DNA, from retrotransposons or retroviruses such as HIV, can 
become susceptible to deamination during reverse transcription, replication, and RNA-
polymerase mediated transcription, because they involve ssDNA intermediates.  Although HIV 
restriction is the main system studied for the effect of Apo3 enzymes, the action of Apo3 
enzymes is largely blocked by HIV Vif which causes their ubiquitination and degradation in the 
proteasome (Conticello et al., 2003; Marin et al., 2008; Marin et al., 2003; Sheehy et al., 2003; 
Stopak et al., 2003).  Unfortunately human DNA can also be susceptible to deamination during 
transcription (Love et al., 2012; Peled et al., 2008).  Therefore, this form of retroelement defense 
may come at a cellular cost.  This has become more apparent in recent years as members of the 
Apo3 family have been identified such as Apo3A and Apo3H that localize in both the nucleus 
and the cytoplasm (Chen et al., 2006; Li and Emerman, 2011; OhAinle et al., 2008).  Very recent 
data has also determined that Apo3G also enters the nucleus after irradiation of the cell 
(Nowarski et al., 2012).  Apo3A is known to interact with foreign DNA, in monocytes, leading 
to degradation of the DNA through a deamination dependant mechanism (Stenglein et al., 2010) 
as well as the restriction of retrotransposons (Bogerd et al., 2006a; Bogerd et al., 2006b; Chen et 
al., 2006), and can cause detrimental off-target deamination of nuclear DNA (Landry et al., 
2011) or assist in catabolism of DNA (Suspene et al., 2011a).  Apo3H is localized in the 
cytoplasm in most primates, but has become distributed in the cytoplasm and nucleus in humans 
and chimpanzees (Li and Emerman, 2011; OhAinle et al., 2008; OhAinle et al., 2006).  Apo3H 
in humans also sustained two independent mutations that have resulted in destabilization of the 
protein, reducing its half-life (OhAinle et al., 2008).  The sudden shift of Apo3H from the 
cytoplasm to the nucleus may have been sufficient evolutionary pressure to result in the selection 
of a destabilized Apo3H protein if Apo3H were to have caused numerous deaminations in 
nuclear DNA. 
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The reference point for nuclear DNA deaminase research is activation induced cytidine 
deaminase (AID).  AID is closely related in form and catalytic activity to the Apo3 family, but 
has been identified to play a significantly different role in the cell.  AID is a ssDNA cytosine 
deaminase that functions in the adaptive immune system by catalyzing somatic hypermutation 
mutation of the Ig gene resulting in affinity maturation of antibody and class switch 
recombination (reviewed in Di Noia and Neuberger, 2007; Peled et al., 2008).  While these main 
functional mutations are beneficial in that they lead to heredity-independent diversity of Ig 
variable region genes, they can potentially be dangerous for the cell (Hasham et al., 2010).  The 
body has developed mechanisms for controlling aberrant deamination catalyzed by AID (Vuong 
et al., 2009) and Apo3A (Aynaud et al., 2012), but Apo3H has yet to be investigated in this 
regard. 
1.2 Discovery and HIV-APOBEC host-pathogen interaction  
In 2002, research into the requirements for sustainable HIV-1 infection in tissue cultures 
resulted in the discovery of a new family of deoxycytidine deaminase host restriction factors 
(Goff, 2003; Ho and Bieniasz, 2008; Sheehy et al., 2003).  The focus of study at the time was on 
HIV Viral Infectivity Factor (Vif) and how in some cell lines, Vif’s absence resulted in no 
change in HIV infection ability while in other cell lines its absence would allow only a single 
round of viral infection (Pomerantz, 2002).  Sheehy et al. used Vif deleted HIV-1 (Δvif HIV) to 
infect both isogenic permissive (CEM-SS) and non-permissive (CEM) cell lines (Sheehy et al., 
2002).  Common among non-permissive cell types was a protein called CEM15 (now known as 
Apo3G) after the CEM cell used.  Simultaneously, Jarmuz et al. was searching for cDNA 
containing the cytidine deaminase active site sequence from APOBEC1, a related family 
member that deaminates RNA, and found a family of APOBEC genes concentrated on 
chromosome 22 (Jarmuz et al., 2002).  Jarmuz et al. grouped the family of genes as APOBEC1, 
2 or 3 based on DNA sequence homology (Jarmuz et al., 2002).  Since these discoveries in 2002, 
an explosion of research has been dedicated to understanding these deaminases and the role they 
play as host restriction factors. 
HIV reverse transcription, in the absence of Vif, is the putative target for Apo3G 
deamination (Figure 1.1).  In a natural infection HIV codes for and carries with it viral infectivity 
factor Vif, which causes the ubiquitination of Apo3G, thereby preventing its function (Figure 
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1.1) (Conticello et al., 2003; Marin et al., 2008; Marin et al., 2003; Sheehy et al., 2003; Stopak 
et al., 2003).  In the presence of Vif, the amount of Apo3G is severely reduced in the cytoplasm. 
Since Apo3G must be encapsidated in virions to carry out its function, the low amount of cellular 
Apo3G results in less encapsidation and a decreased ability of Apo3G to restrict HIV infection.  
In laboratory Δvif HIV strains Apo3G has been found to package inside of the HIV virion and 
render the progeny virus non-infectious (Sheehy et al., 2002). Apo3G cannot provide any 
protection to an HIV infected cell that is producing virus (Figure 1.1).  However, once the 
infected cell begins production of virus particles, Apo3G is able to bind to the nascent RNA 
genomes and HIV nucleocapsid protein (NC) and enters into the virions (Bach et al., 2008; 
Huthoff and Malim, 2007; Wang et al., 2007).  Apo3G remains in the virus until the particle 
infects another cell (Figure 1.1).   
As the viral core enters the cytoplasm of the target cell, reverse transcription of the 
genomic (+)RNA to (-)DNA begins.  Apo3G can cause C→U deamination of the single strand 
intermediate generated (Figure 1.2).  These uracil lesions become mutations upon synthesis of 
the complementary DNA strand by reverse transcriptase (RT) as it synthesizes the (+)DNA to 
make the dsDNA provirus (Figure 1.2 B).  Specifically, the RNA genome is primed by the 
human tRNALys3 at the primer binding site (PBS) (Figure 1.2 A) (Coffin, 1997).  Reverse 
transcriptase begins synthesizing (-)DNA while the RNaseH domain of other RT molecules, in 
the virion, catalyze the degradation of the RNA component of the now RNA-DNA heteroduplex 
(Figure 1.2 A) (Coffin, 1997).  While the RNA genome is degraded, NC chaperones the first 
strand transfer of the (-)DNA to the 3' R sequence and polymerization of (-)DNA continues 
(Figure 1.2 A) (Coffin, 1997).  The RNaseH activity of RT also exposes sections of single 
stranded (ss) DNA that Apo3G subsequently deaminates (Figure 1.2 A-B) (Yu et al., 2004). 
With (-)DNA synthesis complete, (+)DNA synthesis is primed by RNaseH resistant polypurine 
tracts (PPT) of the RNA-DNA heteroduplex (Figure 1.2) (Coffin, 1997).  Synthesis of the 
(+)DNA ends the opportunity for Apo3G deamination and fixes the uracil lesions as G→A 
transitions on the (+)DNA strand (Figure 1.2 A-B) (See Appendix 7.1).  There is a very low 
potential for repair of these lesions because the process is occurring in the cytoplasm. Apo3G 
cannot act as a post-entry barrier and must be packaged in the virion and can only provide 
protection to subsequently infected cells (Figure 1.1) (Mangeat et al., 2003; Zhang et al., 2003). 
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Regions of the HIV (-)DNA provirus furthest from the PPT second strand primers remain 
single stranded for longer.  This means that the centre and 5' end of the (-)DNA are single-
stranded the longest and most susceptible to Apo3G-mediated deaminations (Suspene et al., 
2006).  This also coincides with the catalytic orientation specificity of Apo3G (3'→5') where the 
enzyme scans in both directions but prefers to deaminate cytosines furthest from the 3' end of 
ssDNA (Chelico et al., 2006).  It is thought that the kinetics of reverse transcription along with 
the processivity characteristic of Apo3G results in a gradient of mutations 3' to the PBS as 
demonstrated in vitro (Feng and Chelico, 2011) and in database studies of clinical HIV strains 
(Suspene et al., 2006).  These induced mutations occur in great numbers and can functionally 
inactivate HIV (Mangeat et al., 2003; Zhang et al., 2003).  Apo3G may cause the gradient of 
deaminations found in the HIV strains because it is processive and able to catalyze multiple 
deaminations during a single interaction.  An Apo3 enzyme that is not processive has never been 
tested on an actively reverse transcribing substrate for its ability to cause multiple deaminations.  
A non-processive Apo3 enzyme will allow for the differentiation between the roles that 
processivity of the deaminase play versus the kinetics of reverse transcription (i.e. availability of 
single stranded intermediates) in the accumulation of deaminations. 
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Figure 1.1 Apo3G interaction with HIV-1.  (1) Wild type HIV-1 produces viral infectivity 
factor (Vif) that interacts with the transcription factor CBF-β for stability (Jager et al., 2012; 
Zhang et al., 2012) and the cellular ubiquitination pathway to cause degradation of Apo3G 
(Conticello et al., 2003; Marin et al., 2008; Marin et al., 2003; Sheehy et al., 2003; Stopak et al., 
2003).  As a result, the virus is unaffected by Apo3G inhibition.  (2) In a Vif deficient HIV-1 
infection, Apo3G is not degraded and remains at a concentration where it binds to HIV genomic 
RNA and nucleocapsid protein (NC).  Apo3G then travels within the virion to the next cell.  
Upon target cell infection, packaged Apo3G is able to access the initial steps of reverse 
transcription where it can cause cytosine deaminations (C→U) of (-)DNA.  DNA uracil lesions 
remain unrepaired in the cytoplasm and are fixed as G→A mutations by RT polymerase activity.  
The provirus can acquire numerous mutations (termed hypermutation) that result in its functional 
inactivation. 
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A 
 
 
B 
Genomic RNA AAAGGGCCUGUCGACCCUUUGGGC  
(-)DNA synthesis      ←GGACAGCTGGGAAACCCG  
 
 
RNaseH RNA degradation AA      TG  A   CTT      RNA degradation occurs 
 TTTCCCGGACAGCTGGGAAACCCG nonlinearly 
 
 
Apo3G catalyzed deamination TTTUCCGGACAGCTGGGAAAUCCG  
 
 
(+)DNA synthesis AAAAGGCCTGTCGACCCTTTAG→ Seals in G→A mutation 
 TTTUCCGGACAGCTGGGAAAUCCG  
  
PPT
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Figure 1.2 HIV-1 reverse transcription.  A, HIV-1 replication is primed by human tRNALys,3 
binding to the primer binding site (PBS).  RNA is depicted in black and DNA is depicted in red.  
Reverse transcriptase (RT) activity begins (-)DNA synthesis while the RNaseH activity of RT 
begins degrading the RNA of the RNA-DNA hybrid.  Once the RNA is degraded, nucleocapsid 
protein (NC) chaperones the first strand transfer.  Negative strand DNA elongation continues 
along with RNaseH degradation of the RNA genome with the exception of the two polypurine 
tracts (PPT) which are RNaseH resistant.  Positive strand DNA synthesis is primed by the 
remaining RNA heteroduplexed PPT regions and carried out by RT.  Once (+)DNA elongation is 
complete NC chaperones the circularization of the proviral DNA (not shown) to complete 
synthesis.  Abbreviations are: R, repeated sequence; U5, unique 5'-region; PBS, primer binding 
site; PPT, polypurine tract; U3, unique 3'-region.  B, Uracil lesions are converted into mutations 
during HIV reverse transcription.  Highlighted nucleotides indicate lesions and subsequent 
mutations.  Panel A adapted from Coffin 1997. 
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1.3 Apo3 family 
The APOBEC3 (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3) 
enzymes are a group of seven enzymes that function in innate immunity (Chiu and Greene, 
2008).  They are named Apo3A, Apo3B, Apo3C, Apo3DE, Apo3F, Apo3G, and Apo3H and are 
all located in a gene cluster located on chromosome 22 (Chiu and Greene, 2008; Jarmuz et al., 
2002).  Of these seven members, three have a single zinc (Zn)-coordinating deaminase domain 
(Apo3A, Apo3C, and Apo3H) and four have a double zinc-coordinating deaminase domain 
(Apo3B, Apo3DE, Apo3F, and Apo3G) (Figure 1.3 A) (Bonvin and Greeve, 2007; Chiu and 
Greene, 2008; Hache et al., 2005; Jarmuz et al., 2002).  For the double deaminase domain 
enzymes, only the C-terminal domain is catalytically active (Jarmuz et al., 2002; Navarro et al., 
2005).  There are three distinct Z-domain sequences (Z1, Z2, and Z3) (Figure 1.3 B) (LaRue et 
al., 2009).  Apo3 enzymes function both by causing hypermutations through deamination of 
cytosine to uracil (Mangeat et al., 2003; Zhang et al., 2003), and by binding to RNA of 
retroelements (Bach et al., 2008; Chiu et al., 2006; Huthoff and Malim, 2007; Wang et al., 
2007). 
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Figure 1.3 Z deaminase domain expansions.  A, APOBEC3 enzymes are divided into two 
groups, the single and double Zn-coordinating deaminase domains.  In the family members with 
double deaminase domains, the CD2 domain is catalytically active while the CD1 domain is not.  
B, This diagram shows the expansion of the Z2 deaminase domain.  The Z3 domain was not 
expanded to other family members.  Panel B is adapted from LaRue et al. (LaRue et al., 2009).
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APOBEC3 enzymes are localized in either the cytoplasm (Apo3F and Apo3G), the 
nucleus (Apo3B) or both (Apo3A, Apo3C, Apo3DE, Apo3H) (Table 1.1) (Chiu and Greene, 
2008).  While clinical research on the effectiveness of these enzymes is in its infancy, initial 
results demonstrate that their up regulation/increased concentration has a positive correlation 
with better prognoses of patients with HIV (Biasin et al., 2007; Jin et al., 2005; Koning et al., 
2009; Land et al., 2008; Pace et al., 2006; Refsland et al., 2010; Ulenga et al., 2008; Vazquez-
Perez et al., 2009) and there are many published articles demonstrating their effectiveness in 
vitro against a multitude of retroelements and viruses with ssDNA intermediates including 
Human Papilloma Virus (Vartanian et al., 2008), Herpes Simplex Virus-1 and Epstein Barr Virus 
(Suspene et al., 2011b), and parvovirus (Chen et al., 2006).  The APOBEC3 enzymes comprise a 
potentially highly effective defense against HIV, the main model system in which they are 
studied.  Apo3G is the most effective at improving a patient’s ability to fight HIV-1 as 
determined in clinical studies (Biasin et al., 2007; Bishop et al., 2004; Jin et al., 2005; Koning et 
al., 2009; Land et al., 2008; Pace et al., 2006; Refsland et al., 2010; Ulenga et al., 2008; 
Vazquez-Perez et al., 2009); however, in most cases it is blocked from acting as a viral 
restriction factor because of the Vif protein of HIV-1 (Conticello et al., 2003; Marin et al., 2003; 
Sheehy et al., 2003; Stopak et al., 2003).  Vif functions by interacting with Apo3 enzymes 
(Marin et al., 2008; Sheehy et al., 2002; Sheehy et al., 2003), and causing the ubiquitination and 
subsequent proteasomal degradation of Apo3G, Apo3F, and Apo3DE most efficiently (Figure 
1.1) (Conticello et al., 2003; Marin et al., 2008; Marin et al., 2003; Sheehy et al., 2003; Stopak 
et al., 2003).  In people with an above average Apo3G expression level or who are infected with 
a Δvif HIV-1, Apo3G can restrict HIV by becoming encapsidated into virions (Albin and Harris, 
2010) (Figure 1.2). 
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Table 1.1 Physical attributes of various Apo3 family enzymes. 
Enzyme Molecular 
Mass 
Deamination 
Motif 
 Nuclear 
Localization 
Cytoplasmic 
Localization 
Reference 
Apo3A 23.0 kDa 5’TTC  ~50% ~50% (Chen et al., 2006) 
Apo3H 
 
 
23.5 kDa 5’CTC HapI 
Hap II 
Hap VII 
64% 
7.8-40.8% 
46.5% 
36% 
59.2-92.2% 
53.5% 
(Li and Emerman, 
2011; Zhen et al., 
2012) 
Apo3G 46.4 kDa 5’CCC   >90% (Chen et al., 2006; 
Yu et al., 2004) 
AID 
 
24.0 kDa 5’WRC Activated B cell 
Resting B cell 
5-15% 
>95% 
85-95% (Bransteitter et al., 
2004; McBride et 
al., 2006; Pham et 
al., 2003) 
W denotes A or T; R denotes A or G; underlined C is deaminated; Hap denotes haplotype 
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Many of the APOBEC3 enzymes have not been assigned a physiological function.  The 
current understanding of these enzymes is that they act primarily in an antagonistic fashion 
against retroviruses and retroelements (Chiu and Greene, 2008), but other possible cellular roles 
are only beginning to emerge.  For example, recent evidence shows that Apo3G may also act in 
DNA damage repair by entering the nucleus and interacting with double strand breaks (Nowarski 
et al., 2012).  However, a role in HIV restriction is likely because there are specific viral 
proteins, HIV-1 Vif and HIV-2 Vpx, which counteract APOBEC3 enzymes.  The APOBEC3 
proteins could also be contributing to viral evolution by catalyzing an insufficient density of 
deaminations which result in a virus that is mutated but not functionally inactivated (Jern et al., 
2009; Kim et al., 2010; Mulder et al., 2008; Pillai et al., 2008; Sadler et al., 2010). 
1.3.1 Apo3G 
The first member of the Apo3 family discovered was Apo3G (Sheehy et al., 2002).  
Apo3G is often used to describe the entire family of Apo3 enzymes, but it is becoming apparent 
that each of the family members present a unique set of characteristics.  Apo3G is highly 
processive, meaning that it can cause successive deaminations during a single substrate 
interaction (Chelico et al., 2006; Chelico et al., 2010).  The processive nature of Apo3G is due to 
its double domain structure where the C-terminal CD2 domain is catalytically active for 
deamination and the N-terminal CD1 domain mediates processivity and polarity (Chelico et al., 
2010).  Apo3G preferentially catalyzes deaminations from 3' to 5' (Chelico et al., 2006; Chelico 
et al., 2010).  Apo3G scans DNA by facilitated diffusion (Berg et al., 1981; Halford and Marko, 
2004) where both jumping and sliding motions occur (Chelico et al., 2006; Chelico et al., 2010; 
Feng and Chelico, 2011).  Apo3G is primarily found in the cytoplasm where it does not come 
into contact with host DNA (Chiu and Greene, 2008).  Apo3G deaminates the motif 5'CCC 
(underlined C is deaminated), a sequence preference that appears to be unique to Apo3G (Yu et 
al., 2004).  The paradigm set by Apo3G is shown in Figure 1.1 where the Apo3 enzyme must be 
incorporated into the HIV particle for effective restriction.   
Until very recently it was believed that HIV-1 was the sole target for Apo3G activity.  A 
new study has demonstrated that Apo3G is able to enter the nucleus upon DNA damage from 
radiation (Nowarski et al., 2012).  Once in the nucleus, Apo3G localizes to double strand breaks 
and appears to bind single strand overhangs and bring the ends together (Nowarski et al., 2012).  
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End joining is dependent on deaminations catalyzed by Apo3G, as demonstrated by the finding 
that deamination negative mutants are unable to successfully aid in repair (Nowarski et al., 
2012).  Apo3G was shown to be effective in inducing repair of the double strand breaks through 
uracil-induced recruitment of DNA repair proteins (Nowarski et al., 2012).   
1.3.2 Apo3A 
Apo3A is a single domain ssDNA cytosine deaminase that is located in both the nucleus 
and the cytoplasm (Chen et al., 2006).  Apo3A contains the Z1-type zinc coordinating sequence 
(LaRue et al., 2009) which is in common with the C-terminal catalytic domain of Apo3G (CD1, 
Z2 binding/processivity; CD2, Z1 catalytic) (Chelico et al., 2010; Feng and Chelico, 2011; 
Hache et al., 2005; Navarro et al., 2005).  It is highly expressed in keratinocytes (Madsen et al., 
1999) and in periphery blood monocytes (Chen et al., 2006; Stenglein et al., 2010).  Apo3A has 
a predicted charge of -2.5 at a pH of 7.4, making it unique among Apo3 enzymes which are more 
close to neutral or positively charged at pH 7.4.  No crystal structure has been determined for 
Apo3A to date, so predictions regarding charge remain sequence based.  Apo3A is known to 
preferentially catalyze deamination of (C→U) in a 5'TTC sequence context from basic assays 
using purified protein (Chen et al., 2006).  Apo3A has not been extensively studied 
biochemically. 
Apo3A is extremely efficient at inhibiting Long Terminal Repeat (LTR) and non-LTR 
retroelements (Bogerd et al., 2006a; Chen et al., 2006; Muckenfuss et al., 2006).  Apo3A has 
also been shown to be very effective in preventing the replication of Adeno-Associated Virus, a 
trait not shared with other Apo3 enzymes (Chen et al., 2006).  Over expression of Apo3A has 
been shown to cause hypermutation of Hepatitis B Virus in vivo (Abe et al., 2009).  Apo3A has 
been demonstrated to inhibit Human Papilloma Virus types 1 and 16 (Vartanian et al., 2008).  
Inhibition of HIV-1 virus by Apo3A has recently been demonstrated in dendritic cells (Berger et 
al., 2011), macrophages (Berger et al., 2011; Koning et al., 2011), and monocytes (Peng et al., 
2007) and may contribute in part to the inability of HIV to infect these cells.  This activity is 
unique in the Apo3 family since it appears to occur by Apo3A inhibiting virus upon entry to the 
target cell.  Apo3A does not package into the HIV nucleocapsid which prevents from Apo3A 
interacting with the ribonucleoprotein complex (Chen et al., 2006; Chiu and Greene, 2008; 
Goila-Gaur et al., 2007).  Agular et al. created a fusion protein with Apo3A and HIV Vpr that 
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was able to enter the viral core (Aguiar et al., 2008).  The Apo3A-Vpr fusion protein 
demonstrated that inhibition of HIV was deamination dependent and required capsid localization.  
Goila-Gaur et al. created protein fusions containing Apo3A fused with the N-terminal half of 
Apo3G (Goila-Gaur et al., 2007).  Similarly, in this experiment they were able to show that the 
fusion protein was able to inhibit HIV-1 as Apo3A could reach the viral core. 
Research by Berger et al. has demonstrated that the HIV-2 Vpx protein antagonizes 
Apo3A in human monocytes (Berger et al., 2010).  Targeting by viral factors is a hallmark of a 
cellular system that evolved to fight viruses and these systems are often highly specific.  The 
interactions observed between Apo3A and HIV-2 indicates that they may have pressured the 
evolution of each other.  It is emerging that Apo3A is a potent antiretroelement and antiretroviral 
protein where expression of Apo3A is upregulated by interferon-α (Peng et al., 2007; Refsland et 
al., 2010; Stenglein et al., 2010).  Apo3A is also upregulated by CpG DNA (Stenglein et al., 
2010). 
Along with potent inhibition of endogenous retroelements, Apo3A has been found in high 
levels in colorectal adenocarcinoma, Burkitt’s lymphoma, and chronic myelogenous leukemia 
cell lines (See references within (Chiu and Greene, 2008)).  In 2011, Landry et al. demonstrated 
that Apo3A was able to cause genomic instability and subsequent double strand breaks in U2OS 
cells (an osteosarcoma cell line) (Landry et al., 2011).  They found that the damage caused by 
Apo3A required the catalytic deamination activity of Apo3A and that double strand breaks could 
only occur in the presence of uracil-N glycosylase (Landry et al., 2011).  The DNA damage 
detected in these experiments was unique to Apo3A as both Apo3C and Apo3G did not 
demonstrate similar DNA damage (Landry et al., 2011).  Landry et al. found that DNA 
replication made nuclear DNA susceptible to Apo3A deamination (Landry et al., 2011).  Related 
family member, AID, has been found to cause aberrant deamination of nuclear DNA during 
nuclear DNA transcription (Bransteitter et al., 2004; Pham et al., 2003).  To date, DNA 
transcription, which produces transiently single stranded DNA, has not been investigated as a 
target for Apo3A deamination. 
Recently the human tribbles 3 protein (TRIB3) has been identified as  being able to 
interact with Apo3A and modulate its activity(Aynaud et al., 2012).  This protein essentially 
protects nuclear DNA from Apo3A damage.  If left unchecked, Apo3A damage begins to 
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resemble that of uncontrolled AID which causes massive amounts of nuclear DNA damage 
(Aynaud et al., 2012; Hasham et al., 2010).  Together Apo3A and AID demonstrate that nuclear 
DNA is extremely vulnerable to attack by cellular deaminases. 
1.3.3 Apo3H 
Apo3H is active against retroviruses such as HIV-1 when overexpressed in tissue culture 
(Dang et al., 2008; Harari et al., 2009; OhAinle et al., 2008; Tan et al., 2009).  Apo3H induces 
mutations in retroviral DNA by deaminating in a 5'CTC context where the underlined C is 
preferentially deaminated.  Apo3H is a potent inhibitor of MusD and LINE-1 retrotransposons 
(OhAinle et al., 2008; Tan et al., 2009).  Apo3H is an inhibitor of HPV types 1 and 16 
(Vartanian et al., 2008).  That being said, stable Apo3H is only found in a small fraction of the 
human population with the vast majority of humans expressing only a form of Apo3H that is 
quickly degraded (Harari et al., 2009; OhAinle et al., 2008; Wang et al., 2011). 
Apo3H was destabilized in human evolution not once, but twice, through two 
independent mutations (R105G and ΔN15) (OhAinle et al., 2008).  These mutations are 
distributed within the human population resulting in at least seven haplotypes (Hap) (Wang et 
al., 2011).  Both ΔN15 and R105G destabilize the protein, reducing its half life (OhAinle et al., 
2008).  More recent research has determined that there are subcellular localization differences 
between the Apo3H haplotypes and that localization appears to be dependent on Arg 105 (Table 
1.1).  Hap I (15N, 105G, 121K, 178E) is localized in both the nucleus (64%, determined by 
staining) and cytoplasm (36%) but has a reduced half-life as well as little anti-retroviral activity 
(Li and Emerman, 2011; Zhen et al., 2012).  It appears to enter the nucleus by passive diffusion 
due to its relatively small size (23.5 kDa) (Li and Emerman, 2011).  Hap II (15N, 105R, 121E/D, 
178D) remains in the cytoplasm (59.2-92.2%, determined by staining) where it is believed to be 
actively retained though a mechanism that has not been determined (Li and Emerman, 2011; 
Zhen et al., 2012).  Of particular interest is Hap VII (15N,105R, 121K, 178E) which is used in 
this M. Sc. research because it contains the ancestral polymorphism 105R, reinstating its 
stability, and in addition it is partially retained in the nucleus (46.5% nuclear, 53.5% 
cytoplasmic) where it may interact with nuclear DNA (Li and Emerman, 2011). 
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The distribution of the haplotypes indicates that ancestral alleles for Apo3H (Hap II) are 
found in 51-52% of people of African descent, 10-18% of people of European descent, and 3-4% 
of people of East Asian descent (OhAinle et al., 2008).  Despite the decreased stability of Hap I a 
study in 2011 found that it was able to confer some protection from HIV-1 (Cagliani et al., 
2011).  Species divergence between humans and chimpanzees predates the acquisition of both 
the R105G and ΔN15 mutations (OhAinle et al., 2008).  It was due to these destabilizing 
mutations that Apo3H was not initially found along with the other Apo3 family members 
(Jarmuz et al., 2002; Sheehy et al., 2002), but was discovered later upon sequencing of the 
human genome (Conticello et al., 2005; Wedekind et al., 2003). 
In addition to the two destabilizing mutations (R105G and ΔN15), human Apo3H (all 
haplotypes) contain a premature termination codon (PTC) that results in the deletion of 29 amino 
acids at the C-terminal end of the protein that is present in Apo3H of other primates (Dang et al., 
2008).  OhAinle et al. published a report indicating that elimination of the premature termination 
codon (PTC) drastically changed the subcellular localization of Apo3H Hap I allowing it to 
localize to the nucleus (OhAinle et al., 2008).  They inferred that the PTC removed a putative 
nuclear export signal and that in its absence Apo3H Hap I had become a nuclear enzyme 
(OhAinle et al., 2008).  Deletion of the PTC of Apo3H allowed for Apo3H retention in the 
nucleus where it could contact nuclear DNA. 
Apo3H is unique among the Apo3 family of cytosine deaminases in terms of its 
sequence.  As discussed in Section 1.3, the Apo3 family contains seven family members 
(Apo3A-H).  Apo3A-G isoforms are each the result of expansion by duplication of the Z1 and 
Z2 domains while Apo3H is a Z3 type has not been duplicated in all mammals examined (Figure 
1.3) (Conticello et al., 2005; LaRue et al., 2009; OhAinle et al., 2006).  There are two possible 
explanations for the absence of expansion of Apo3H.  First, it could be that the function of 
Apo3H predates mammalian evolution and that there was little use for it to remain (OhAinle et 
al., 2006).  This idea was countered by OhAinle et al. in 2006 when they found that Apo3H had 
undergone positive selection, concluding that in recent evolution Apo3H was sustaining 
mutations at a similar rate to Apo3G (OhAinle et al., 2006; Sawyer et al., 2004), a known HIV-1 
inhibitor (Sheehy et al., 2002).  A second explanation for the lack of expansion of the Apo3H-Z3 
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type cytosine deaminase is that it became toxic to the cell due to a subcellular localization 
change that allowed entry into the nucleus (OhAinle et al., 2008). 
Control mechanisms have been identified in the phosphorylation of AID (Vuong et al., 
2009) and the binding partner TRIB3 for Apo3A (Aynaud et al., 2012) to restrain the amount of 
damage done to the host cell but no such mechanism has been found for Apo3H.  Though not 
investigated here, we hypothesise that in lieu of the evolution of a control mechanism in the 
nucleus for Apo3H, evolution resulted in the inactivation of Apo3H. 
Taken together; (i) the strong conservation of destabilizing mutations (R105G and ΔN15) 
sustained in the vast majority of the population, (ii) the ability of human Apo3H to enter the 
nucleus where it comes into close contact with nuclear DNA, and finally (iii) the fact that Z3 
zinc coordinating domain was not selected for expansion, presents compelling evidence that 
Apo3H is detrimental to the cell. 
1.3.4 Activation induced deaminase 
AID is a member of the APOBEC3 type family of ssDNA cytosine deaminases.  It has a 
preference for the 5'WRC motif (W denotes A or T; R denotes A or G; underlined C is 
deaminated) and deaminates ssDNA processively (Bransteitter et al., 2004; Pham et al., 2003).  
AID initiates somatic hypermutation during secondary antibody maturation in a transcription 
dependent manner where U:G mismatches, catalyzed by AID, are repaired by either uracil-N 
glycosylase or by the mismatch repair pathway (MMR) (reviewed in (Di Noia and Neuberger, 
2007; Larijani and Martin, 2012; Peled et al., 2008)).  Even though AID is only able to 
deaminate cytosines, diverse amino acid substitutions are observed due to targeted error prone 
repair involving polη of uracil lesions in antibody diversity regions (McIlwraith et al., 2005).  
The targeting of the error prone repair remains unknown (Larijani and Martin, 2012).  Along 
with mutations occurring at the amino acid level, AID also causes double strand breaks and 
deletion of portions of the immunoglobulin cassette that result in antibody class switching 
(reviewed in (Larijani and Martin, 2012; Stavnezer et al., 2008)).  Removal of uracil from DNA 
causes abasic sites that are prone to DNA strand breakage.  DNA repair of closely spaced uracil 
lesions, which are excised to form abasic sites on both strands of the DNA, can results in double 
strand breaks. 
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To maintain such a potent deaminase in the nucleus could pose problems for the cell.  For 
this reason AID access to the nucleus is tightly controlled.  However, when in the nucleus, AID 
can cause substantial deaminations in nuclear DNA that are repaired by UNG and downstream 
repair pathways.  Yet, this repair is not always error-free as it has now been demonstrated that 
most of the B cell chromosome can be edited by AID when it is recruited to stalled PolII RNA 
polymerase (Liu et al., 2008; Yamane et al., 2011).  With the concerted action of UNG, AID can 
cause massive numbers of double strand breaks which can completely destabilize chromosomes 
(Hasham et al., 2010).  Oncogenes are susceptible to AID deamination because they are highly 
transcribed due to their role in controlling the cell cycle and many proto-oncogenes have been 
identified as inadvertent targets for AID (Gordon et al., 2003; Liu et al., 2008; Muschen et al., 
2000; Pasqualucci et al., 2001; Robbiani et al., 2009).  AID has been found to have a direct link 
to the transformation of certain cell lines in the absence of the tumour suppressor p53 (Robbiani 
et al., 2009).  The main function of AID to enable somatic hypermutation and class switch 
recombination is essential to the immune system so this “collateral damage” must be tolerated by 
the organism and AID cannot be inactivated as is hypothesized for Apo3H which may be 
functionally redundant with other Apo3 enzymes. 
AID can only damage DNA by deamination of cytosine to uracil but the effects can be 
manifested in two ways, each of which requires DNA repair.  Single point mutation repair was 
investigated by Liu et al. who determined that both Ung and Msh2 were needed (Liu et al., 
2008).  It was determined that the efficiency of Msh2 (MMR type repair) was more essential for 
preventing damage (Liu et al., 2008).  They further determined that AID off target activity was 
constantly affecting virtually all genes and that mutations were introduced only in specific genes 
(Ig cassette) due to differences in the repair enzymes recruited to the damaged sites (Liu et al., 
2008).  In 2010, Hasham et al. demonstrated that homologous recombination was required for 
double strand break repair catalyzed by AID (Hasham et al., 2010).  They went on to describe 
how mutations sustained specifically to XRCC2 homologous recombination factor rendered B 
cells extremely unstable because AID double strand breaks could not be repaired (Hasham et al., 
2010).  It has been demonstrated that without high fidelity UNG repair pathways (Liu et al., 
2008) for correction of uracil in DNA, AID can cause malignancy in lymphocytes and B cells 
(Okazaki et al., 2003; Robbiani et al., 2009).  It remains to be determined how error prone 
instead of high fidelity DNA repair is specifically targeted to the Ig genes. 
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There are several levels of control and regulation pertaining to AID.  First, the organism 
as a whole does not express AID in all tissues, AID is normally only found in B cells 
(Muramatsu et al., 2000; Muramatsu et al., 1999; Revy et al., 2000).  In this way, cell types with 
large amounts of transcription are free from AID related pressure.  Second, there are cellular 
regulations in place at the protein level.  AID is upregulated once a B cell is stimulated for 
secondary antibody maturation with TGF-β, IL-4, and CD40L (Muramatsu et al., 1999).  Tight 
regulation, mediated by regulatory immune signalling molecules, ensures that risk is reduced and 
endured only when required.  The immune system, in general, exemplifies the evolutionary 
trade-off between internal sacrifice; i.e. inflammation and cytotoxicity versus defence from 
external threat.  At a cellular level, AID is also found in the cytoplasm where it does not come 
into contact with cellular DNA when the B cell is at rest (not activated).  AID is imported into 
the nucleus as a result of phosphorylation upon B cell activation (McBride et al., 2006; Vuong et 
al., 2009).  Modification of AID through phosphorylation allows the cell tight control over AID 
activity.  Yet other regulatory molecules are being uncovered.  MicroRNA-155 has also been 
associated with down regulation of AID (Teng et al., 2008). 
1.4 Rationale for hypotheses 
Apo3A and Apo3H appear to possess HIV restriction ability in cell-based studies 
(Apo3A, (Berger et al., 2011; Koning et al., 2011); Apo3H, (Dang et al., 2008; Harari et al., 
2009; OhAinle et al., 2008; Tan et al., 2009)) although the mechanism by which the enzymes 
bind ssDNA to scan for cytosines is unknown.  However, Apo3A and Apo3H pose a potential 
problem for cells due to their ability to enter the nucleus (Chen et al., 2006; OhAinle et al., 
2008).  These deaminases can come into contact with cellular DNA that is transiently single 
stranded during transcription and replication and is therefore vulnerable to deamination.  Cells 
must have in place systems to handle the potential cellular DNA damage and to avoid incurring a 
large cellular cost for a mutation-based retroviral restriction system. 
1.5 Hypotheses and objectives 
This research project biochemically characterized the catalytic activity of single domain Apo3 
enzymes Apo3A and Apo3H, on synthetic ssDNA, nascent reverse transcribed DNA and 
transiently formed ssDNA during gene transcription.  This project aims to broaden the 
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understanding of the Apo3 family and question many of the generalities formed based on 
research focused on Apo3G. 
The hypotheses addressed in this project are: 
(1) Processivity is required for efficient restriction of HIV and enzymes not possessing this 
attribute will catalyze markedly fewer deaminations. 
(2) Apo3 enzymes that can localize to the nucleus may cause deamination of nuclear DNA 
during times when it is transiently single stranded during transcription and replication.  
This means that there is a cost versus benefit ratio that would impinge selective pressures 
on the evolution of a mutation-based viral restriction strategy. 
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CHAPTER 2.0 
MATERIALS AND METHODS  
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2.1 Protein production 
Protein production was performed in eukaryotic Sf9 insect cells because previously 
analyzed activity, demonstrated that recombinant Apo3G (unpublished data) and AID (Pham et 
al., 2008) produced from Escherichia coli is 100-fold less active than Sf9 cell expressed Apo3G 
or AID, likely due to the inability of E. coli to correctly phosphorylate the proteins (Demorest et 
al., 2011). 
2.1.1 Production of recombinant baculovirus 
Recombinant proteins were produced as GST fusion proteins using a baculovirus 
expression system.  Genes of interest were cloned into the transfer vector pAcG2T (BD 
Biosciences) by Dr. Chelico using XhoI and EcoRI sites.  To create a baculovirus for Sf9 cell 
(Life Technologies) infection, the transfer vector, pAcG2T, and 5 μL baculovirus DNA were 
mixed and incubated for 5 min at room temperature.  Then, 100 μL of Sf900 II media (Life 
Technologies) was added to the DNA mixture and incubated for another 5 min.  To facilitate 
uptake of the DNA mixture into the cell, we used Cellfectin II Reagent (Life Technologies).  
Cellfectin was prepared by incubating it in 100 μL Sf900 II media for 15 min at room 
temperature.  The Cellfectin and DNA mixture were combined and gently mixed and then 
incubated for 35 min.  A 6-well adherent growth plate was prepared with 1 x 106 cells/well in 2 
of the wells, one for production of virus and one as a growth control.  2 mL of Sf900 II media 
was added to cell containing wells.  The Cellfectin/DNA mixture was then added carefully drop 
by drop to the production well.  The remaining 4 wells of the 6-well plate were filled with sterile 
ddH2O to maintain humidity.  The cells were incubated for 4-5 days at 27°C.  The supernatant 
was transferred to a 1.5 mL tube and centrifuged for 15 min at 100 x g.  Once complete, the 
supernatant was harvested and saved as the initial passage (P0) of the virus.  To passage the 
virus, we prepared 3 T75 cm2 flasks containing 8.4 x 106 cells in 10 mL of Sf900 II media for 
each.  Cells were allowed to adhere for 15 min, then the media was replaced with 15 mL fresh 
Sf900 II media.  To the first flask, 100 μL of P0 was added, to the second 500 μL of P0 was used, 
and to the last flask no virus passage was added so that it could serve as a growth control.  
Infection was monitored for 3 days at 27°C by visual inspection for infection of cells (large 
swollen cells, detachment, and lack of growth).  Virus was passaged (P1) using the lowest 
volume that demonstrated infection (either 100 μL or 500 μL).  Virus was passaged 2 times more 
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using 100 μL of supernatant (P2, P3).  The next step was to amplify the virus for the bulk 
inoculation.  To make the P4, we prepared a 50 mL suspension flask of cells at 2 x 106 cells/mL 
and inoculated it with 100 μL of P3.  The flask was incubated for 48 hours at 27°C.  The solution 
was then filter sterilized and stored at 4°C.  This produces a virus stock of approximately 1 x 108 
pfu/mL for a 1500 bp gene or 1 x 1010 pfu/mL for a 750 bp gene as determined by plaque assays 
previously done in our lab. 
2.1.2 Protein Expression 
The optimal amount of virus to add to a culture for protein is empirically determined by 
conducting small scale infections and purifications.  Sf9 cells are infected with virus when they 
reach a cell density of 2 x 106 cells/mL in suspension culture.  Cells are grown on a rotary shaker 
at 27°C at 122 rpm.  It was determined that an MOI of 1 was optimal for Apo3A and Apo3H 
Hap VII (referred to as Apo3H for simplicity) for 72 h.  It has been previously determined that 
an MOI of 1 for 72 h is optimal for Apo3G expression (Chelico et al., 2008).  Cells were pelleted 
at 100 x g for 15 min and washed with phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 2 mM KH2PO4) were frozen at -80°C for purification at a later time. 
2.1.3 Protein purification 
A cell pellet from 1 L of infected Sf9 culture was defrosted on ice for 45 min and 
resuspended in 20 mL of lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-
100, 10 mM NaF, 10 mM NaH2PO4·H2O, 10 mM Na4O7P2·10H2O, 10% (v/v) glycerol, 10 mM 
DTT, 1 protease inhibitor tablet (Roche)) with fresh DTT added to 10 mM along with 1 protease 
inhibitor tablet (Roche), and 40 μg/mL of RNase A (Qiagen).  The mixture was then gently 
rocked at 4°C for 45 min.  An additional 40 μg/mL of RNase A was added before the lysate was 
sonicated for 1.5 min at 50% output on Setting 5 (Branson Sonifier 450).  Sonication ensured 
complete cell lysis and sheared nucleic acids, especially RNA which is known to purify with 
Apo3G and AID enzymes (Bransteitter et al., 2003).  Cellular debris was pelleted by 
centrifugation at 4°C for 1 hour at 20 000 x g.  In the mean time, 1.5 mL of Glutathione 
Sepharose 4B beads (GE Healthcare) were washed twice with 40 mL PBS (137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) by spinning for 1 min at 500 x g.  Lysate was then 
removed from the pellet, 20 μg/mL of RNase A added, and incubated with the washed beads for 
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2 hours at 4°C on a gyro rocker.  Beads were then spun for 15 min at 500 x g and the lysate was 
discarded.  The beads were then resuspended in PBS Suspension buffer (10 mL 1% Triton X-
100, 1X PBS, 500 mM NaCl) and transferred to a 20 mL disposable filter column (Bio-Rad).  
The filter column was then washed with consecutive 10 mL volumes of modified chilled PBS 
buffers as follows: PBS Suspension buffer; 1 M NaCl in 1X PBS; and 500 mM NaCl in 1X PBS.  
The final wash was a 10 mL of Digestion buffer (50 mM Tris pH 7.4, 250 mM NaCl, 1 mM 
DTT, 10% glycerol).  The GST fusion proteins were then digested with Thrombin (25 units/mL) 
for 16 h at 4°C (Apo3A and Apo3H) or 21°C (Apo3G).  The overnight digestion was collected 
and additional digestion buffer was used to elute the protein.  A Bradford assay (BioRad) was 
used to determine when no additional protein was eluting from the beads.  The eluted fractions 
were concentrated using centrifugal concentrators (Millipore) by using consecutive 10 min 
centrifugation at 2000 x g until an appropriate volume was reached.  Sample was mixed between 
centrifugations to minimize precipitation.  Protein purity was confirmed with SDS-PAGE and 
determined to be ≥95% (Figure 2.1). 
 
Figure 2.1 Apo3A and Apo3H enzyme purity verification.  Apo3A and Apo3H were resolved 
on a 12% SDS-PAGE gel and stained with coomassie. A, Apo3A (23.0 kDa) resolves as a 
doublet of two isoforms ~19 kDa in size consistent with Chen et al. 2006 and Bogerd et al. 
2006a.  B, Apo3H (23.5 kDa) resolves as a ~18 kDa protein.  This gel demonstrates that the 
enzymes are >95% pure.   
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2.2 Site-directed mutagenesis 
The sequence available for Apo3H (NIH accession bc069023) was obtained as a clone 
(OpenBio Systems) and contained the R105G mutation that results in a reduced half-life 
(OhAinle et al., 2008).  The mutation was reversed by using site directed mutagenesis from the 
2-step protocol of Wang and Malcolm (based on the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene)) (Wang and Malcolm, 1999).  This created an Apo3H Hap VII clone (Wang et al., 
2011).  Primers used were: Apo3H G105R forward primer 5' GCT CAC GAC CAT CTG AAC 
CTG CGC ATC TTC GCC TCC CGC CTG and Apo3H G105R reverse primer 5' CAG GCG 
GGA GGC GAA GAT GCG CAG GTT CAG ATG GTC GTG AGC. 
Two initial PCR reactions were set up with the template.  The reactions were primed in 
the forward direction or the reverse direction as follows: dNTPs, 10 mM; Apo3H G105R SDM 
forward primer or Apo3H G105R SDM reverse primer, 0.5 μM; pAcG2T-A3H template 50 ng; 
5X Phusion HF buffer (Stratagene), 1X; Phusion DNA polymerase (NEB), 1U; ddH2O was 
added to a final volume of 50 μL.  The first PCR cycle was set up as follows: 98°C for 60 sec to 
denature and 98°C for 10 sec, 68°C for 10 sec, 72°C for 2.5 min cycled 2X.  25 μL of the initial 
PCR reaction with forward primer was mixed with 25 μL of the initial PCR reaction with the 
reverse primer.  An additional 1U of Phusion DNA polymerase was added and the mixture was 
then subjected to another PCR reaction: 98°C for 60 sec to denature and 98°C for 10 sec, 68°C 
for 10 sec, 72°C for 2.5 min cycled 29X.  The parental template DNA was digested with 10U of 
Dpn I (NEB) for 1 hour at 37°C.  DH5α cells were transformed by the heat shock method and 
select transformed colonies were grown in order for the contained plasmid to be purified.  
Sequencing was done at the National Research Council (Saskatoon, Saskatchewan). 
2.3 Deamination assay 
DNA substrates were designed based on those used in similar assays performed by 
Chelico et al. 2006 and were synthesized by TriLink Biotechnologies with an internal fluorescein 
label as indicated in Table 2.1.  Apo3A, Apo3H, and Apo3G were reacted at 20-50 nM with 100 
nM or 500 nM fluorescein (Fam)-labeled ssDNA in Reverse Transcriptase Buffer (50 mM Tris, 
pH 7.5, 40 mM KCl, 10 mM MgCl2, 1 mM DTT).  Reactions were incubated for 2.5-30 min at 
37°C.  Reactions were stopped between 2-30 minutes by mixing 10 μL reaction with 30 μL 
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phenol chloroform isoamyl alcohol (25:24:1) and 20 μL ddH2O and vortexing for 30 sec.  DNA 
was extracted and excess phenol was cleared with a chloroform extraction using Phase Lock 
Tubes as per manufacturer’s instruction (5-Prime).  DNA samples were then incubated with 
uracil-DNA glycosylase (UDG, New England Biolabs) for 60 min at 37°C to allow for uracil 
lesions to become abasic sites.  Samples where then heated to 85°C for 10 min with 0.2 mM 
NaOH to induce breakage at abasic sites for detection of deamination (Chelico et al., 2006).  
10μL of DNA samples were run on an 8 cm acrylamide denaturing gel (10%, 16%, or 20% 
Acrylamide:Bis-Acrylamide 19:1, 8 M urea, 1X TBE Buffer (90 mM Tris, 90 mM Boris acid, 2 
mM EDTA pH 8.0)) in 1X TBE Buffer at 18.8 V/cm until the Xylene Cyanol Blue dye reached 
three quarters of the length of the gel.  Gel band intensities were determined with a Typhoon Trio 
(GE Healthcare) multipurpose scanner or Pharos FX Scanner (BioRad) and integrated gel band 
intensities were quantified using ImageQuant software (GE Healthcare).  The specific activity 
was determined under single-hit conditions (Creighton et al., 1995) by calculating the pmoles 
substrate used per minute for a microgram of enzyme. 
2.3.1 Processivity analysis 
The processivity factor was calculated as previously described (See Appendix 7.2) 
(Chelico et al., 2006; Chelico et al., 2009).  In brief, the value is determined by comparing the 
deaminations which occurred at two sites on an ssDNA substrate (5'C & 3'C) to the calculated 
expected value of deaminations which would occur at both motifs if the events were independent 
(not processive).  The expected value was calculated using the probability rule that the frequency 
of two independent events occurring is the product of their frequencies.  The two events 
considered are the total deaminations occurring at the 5'-proximal C and at the 3'-proximal C.  
Reactions were performed under single hit conditions to ensure that a single Apo3 was 
interacting with a given ssDNA substrate.  
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Table 2.1 Substrates used for deamination and rotational anisotropy assays. 
Name Sequence
L3 TTC DNA (deamination assay) AAA GAG AAA GTG ATA TTC A [Fam-dT] ATT 
CAT AGA GTA AAG TTA GTA AGA TGT GTA AGT 
ATG TTA A
L12 TTC DNA (deamination assay) AAA GAG TTA GTG AGA TTC AAA ATT [Fam-
dT] AGA GAT TCA AAT GTT AGA TAT GTT AAT 
GTG TGT GAT GAT GTT GA 
L28 TTC DNA (deamination and 
rotational anisotropy 
AAA GAG AAA GTG ATA TTC AAA GAG TAA AGT 
[Fam-dT] AGA TAG AGA GTG ATA TTC AAA 
GAG TAA AGT TAG TAA GAT GTG TAA GTA TGT 
TAA 
L28 TTC DNA Complement 
(deamination assay) 
TTA ACA TAC TTA CAC ATC TTA CTA ACT TTA 
CTC TTT GAA TAT CAC TCT CTA TCT AAC TTT 
ACT CTT TGA ATA TCA CTT TCT CTT T 
L28 TTC RNA Complement 
(deamination assay) 
UUA ACA UAC UUA CAC AUC UUA CUA ACU UUA 
CUC UUU GAA UAU CAC UCU CUA UCU AAC UUU 
ACU CUU UGA AUA UCA CUU UCU CUU U 
L61 TTC DNA (deamination assay) GAA TAT AGT TTT TAG TTC AAA GTA AGT GAA 
GAT AAT [Fam-dT] TAG AGA GTT GTA ATG 
TGA TAT ATG TGT ATG AAA GAT ATA AGA TTC 
AAA GAG TAA AGT TGT TAA TGT GTG TAG ATA 
TGT TAA 
L28 CTC DNA (deamination assay 
and rotational anisotropy) 
AAA GTG AAA GTG ATA CTC AAA TTT AAA AGT 
[Fam-dT] AGA TAG AAG GTG ATA CTC AAA 
TAT GAA AGT TAG TAA GAT GTG TAA GTA TGT 
TAA 
L28 CTC Reversed Orientation 
(deamination assay) 
AAA TAT GAA AGT TAG TAA GAT GTG TAG ATA 
AGT TAA ATA CTC AAA TTT AAA AGT [Fam-
dT] AGA TAG AAG GTG ATA CTC AAA GTG AAA 
GTG 
L61 CTC DNA (deamination assay) GAA TAT AGT TTT TAG CTC AAA GTA AGT GAA 
GAT AAT [Fam-dT] TAG AGA GTT GTA ATG 
TGA TAT ATG TGT ATG AAA GAT ATA AGA CTC 
AAA GTG AAA AGT TGT TAA TGT GTG TAG ATA 
TGT TAA 
L61 DNA Block (deamination assay) CTT TCA TAC ACA TAT ATC AC 
L61 RNA Block (deamination assay) CUU UCA UAC ACA UAU AUC AC 
L28 CCC DNA (deamination assay) AAA GAG AAA GTG ATA CCC AAA GAG TAA AGT 
[Fam-dT]AGA TAG AGA GTG ATA CCC AAA GAG 
TAA AGT TAG TAA GAT GTG TAA GTA TGT TAA 
 Abbreviation:  Fam is fluorescein.   
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2.4 Steady state rotational anisotropy 
Steady state fluorescence depolarization (rotational anisotropy) was measured for Apo3A, 
Apo3H, and Apo3G binding to Fam-labeled ssDNA specific for Apo3A (5'TTC), Apo3H 
(5'CTC), and Apo3G (5'CCC) (Table 2.1).  Reactions were calculated to a volume of 80 μL and 
contained Fam-labeled ssDNA (15 nM) in Reverse Transcriptase Buffer with a titration of 
Apo3A (0-25 μM), Apo3H (0-0.45 μM) or Apo3G (0-0.70 μM) to achieve saturation of the 
substrate.  Measurements were made at 21°C using a QuantaMaster QM-4 spectrofluorometer 
(Photon Technology International) with a dual emission channel. Samples were excited with 
vertically polarized light at 494 nM (7 nm band pass) and vertical and horizontal emissions were 
measured at 520 nM (7 nm band pass).  Samples were excited for 10 sec at 1 emission 
measurement recorded per 1 sec and averaged for each titration concentration. 
2.5 Multi-angle light scattering assay 
Apo3A (300 µg) was subjected to size exclusion chromatography using a Superdex 
200HR10/300 column (GE Healthcare) connected to an Agilent 1200 HPLC. A solution 
containing 20 mM HEPES pH 7.3 and 150 mM NaCl was used as the elution buffer. 
Chromatography and detection was performed as previously reported (Feng and Chelico, 2011) 
at the Keck Foundation Biotechnology Resource Laboratory at Yale University (Folta-Stogniew 
and Williams, 1999). Data analysis to determine molecular masses was performed with ASTRA 
software (Wyatt, 1993). 
2.6 HIV replication assay 
2.6.1 Reverse transcription reaction 
The model in vitro HIV replication assay and subsequent detection of Apo3 catalyzed 
deamination was performed as described previously (Figure 2.2) (Feng and Chelico, 2011).  A 
synthetic (+) RNA genome was created using in vitro RNA transcription from the vector pET-
Blue-PPT-Prot (Feng and Chelico, 2011) that contained a polypurine tract (PPT), 120 nt of the 
catalytic domain of the HIV-1 protease (prot), and the lacZα complementation fragment.  The 
PPT served as an internal second strand ((+) DNA) primer for the reaction (Coffin, 1997).  The 
prot was used to identify specific amino acid changes that could be induced by Apo3 enzyme-
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mediated deamination, and the lacZα was used as a reporter gene for mutations by blue/white 
screening.  The HIV-1 clone from which the protease gene was amplified was obtained through 
the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 
p93TH253.3 from Dr. Feng Gao and Dr. Beatrice Hahn (Gao et al., 1996). 
To begin the reaction, the RNA genome (50 nM) was heat annealed to a 24-nt DNA 
primer (Feng and Chelico, 2011) (Table 2.2) and incubated with NC (3.0 μM), RT (2.4 μM), and 
dNTPs (500 μM) in Reverse Transcriptase Buffer in the presence or absence of 200 nM of 
Apo3A or Apo3G (Figure 2.2).  Each of the components of the reverse transcription reactions 
were at estimated physiological ratios to the HIV genome as found in the HIV-1 literature 
(Briggs et al., 2004; Coffin, 1997; Zhu et al., 2003) or Apo3G literature (Xu et al., 2007).  The 
reaction mixture was incubated at 37°C for 3 hours.  Reverse transcription was stopped and the 
NC protein filament denatured by the Stopping Solution (0.5% SDS and 2.5 mM EDTA) and 
proteinase K (0.5 mg/mL) (New England Biolabs).  The halted reaction was then incubated at 
room temperature for 30 min.  After the incubation, the DNA was extracted by 
phenol:chloroform:isoamyl extraction.  Excess dNTPs and phenol were removed by using the 
Bio-Spin 6 Kit Columns (BioRad). 
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Figure 2.2 Reconstituted HIV replication system.  Sketch depicting the steps of the 
reconstituted HIV replication system.  The dsDNA product is meant to model a provirus and 
contains 120 nt of the HIV-1 prot gene (2282-2401 nt) and the lacZα (236 nt). 
Table 2.2 Primers used for HIV reverse transcription assay. 
Name Sequence 
PCR Amplification Forward Primer GGG ACT CGA GAT AGG AGG ACA ACT GAA AGA 
AG 
PCR Amplification Reverse Primer GGG CAG GAA TTC GAT ATC TAT ATC 
Plasmid Sequencing Primer CGG CGA CGA CCG GTG AAT TG 
  
NC, RT, Apo3
T7 Transcription
PPT-prot-lacZα
PPT
PCR, Restriction digest
Transform E. coli
Sequence  plasmids from white colonies
PPT
PPT
Ligate into pET Blue vector
Ampicillin selection
RNA ‘viral template’
RNA
DNA Primer
DNA
DNA
DNA
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2.6.2 PCR amplification of deaminated product 
Once purified, the deaminated dsDNA product must be amplified to convert uracil lesions 
to mutations.  The PCR reaction was set up as follows:  deaminated product, 10 μL; dNTPs, 10 
mM; Pfu Cx Buffer (Agilent Technologies), 1X; PfuTurbo Cx Hotstart DNA Polymerase (Agilent 
Technologies), 1U; PCR Amplification Forward primer, 200 ng; PCR Amplification Reverse 
primer, 200 ng.  PCR reaction was adjusted with ddH2O to a volume of 50 μL.  PfuTurbo Cx can 
accurately use uracil as a template. The PCR cycle was as follows: 95°C for 2 min to denature 
the DNA; 95°C for 1 min, 50°C for 1 min, 72°C for 1 min, for 30X.  Amplified fragment size 
was confirmed by using agarose gel electrophoresis (1% agarose).  A successful amplified 
fragment appeared at approximately 350 nt.  Once the size of the fragment was confirmed by gel, 
the sample was cleaned using a PCR clean up kit (Sigma) as per manufacturer’s instructions. 
2.6.3 Restriction digestion and ligation reactions 
The purified dsDNA product was ligated into the pET-ppt-Prot vector using XhoI/EcoRI 
sites which enabled the mutated prot-lacZα to replace the prot-lacZα originally contained in the 
plasmid.  The reaction conditions were as follows:  Cleaned PCR product, 10 μL; EcoRI 
restriction enzyme, 1U; XhoI restriction enzyme, 1U; bovine serum albumin, 1X; NEB Buffer-4 
(NEB), 1X.  The 15 μL reaction was incubated at 37°C for 1.5 hours followed by heat 
inactivation at 65°C for 20 min. 
Following the restriction digestion of the cleaned PCR production, we ligated it into the 
pET-Blue-PPT-Prot transformation vector.  The reaction conditions were as follows:  cleaned 
PCR production (double restriction digested), 2 μL; pET-Blue-1 vector (double restriction 
digested with EcoRI/XhoI and gel purified), 50 ng; T4 DNA ligase (NEB), 1U; and ligation 
buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT), 1X.  The 10 μL reaction 
was incubated at room temperature for 30 min. 
2.6.4 Transformation and plasmid purification 
To screen for mini-proviruses that were deaminated during the reverse transcription 
reaction, they had to be transformed into E. coli for blue/white screening.  Competent DH5α 
cells were made in the lab using the Z-Competent E. coli Transformation Kit (Zymo Research) 
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as per the instruction of the kit.  SOB broth (20 g/L Tryptone, 5 g/L Yeast extract, 10 mM NaCl, 
10 mM MgCl2, 10 mM MgSO4, 0.5 mM KCl, pH 7) was substituted for proprietary Zymobroth 
because competency results were similar.  The heat shock method was used for transformation.  
Cells were plated in triplicate on LB plates containing IPTG, X-gal and Ampicillin. 
White/light blue colony frequency was recorded after a minimum of 16 hours of 
incubation at 37°C.  E. coli cells that received an unmutated ‘provirus’ formed colonies that 
appeared dark blue.  E. coli cells that received a mutated ‘provirus’ formed colonies that 
appeared white or light blue.  The lacZ reporter is very sensitive to both missense (light blue 
colonies) and nonsense (white colonies) mutations (Bebenek and Kunkel, 1995).  Twenty-five 
white/light blue colonies were selected at random for sequencing.  Selected colonies were each 
used to inoculate 5 ml LB-AMP (Ampicillin, 100 μg/mL) broth overnight in culture tubes and a 
streak plate for additional colour verification.  Sequencing of blue colonies demonstrated an 
absence of significant mutations and confirmed that selection of white/light blue colonies did not 
bias the experimental results. 
After 16 hours of incubation, a mini plasmid preparation was performed on each of the 25 
selected colonies.  Cultures were pelleted at 2000 x g for 10 min at 4°C.  Supernatant was 
decanted and the pellet was re-suspended in 250 μL of P1 buffer (50 mM Tris-HCl pH 8.0, 10 
mM EDTA, 100 μg/mL RNase A).  The mixture was then transferred to a 1.5 mL centrifuge tube 
and mixed by inversion (3-4 times) with P2 buffer (200 mM NaOH, 1% W/V SDS).  Once the 
solution clarifies, 350 μL P3 (3 M Potassium Acetate pH 5.5) is added and mixed.  The 
neutralized mixtures were then centrifuged at 15 000 x g for 15 min.  The supernatant was then 
transferred to a fresh 2 mL tube.  Plasmid DNA was precipitated by mixing the sample with 0.7X 
volume of 100% isopropanol and incubating at room temperature for 30 min.  Precipitated 
plasmid DNA was pelleted by centrifugation at 15 000 x g for 20 min.  Isopropanol was removed 
by careful aspiration without disturbing the pellet.  The pellet was then washed with 350 μL 70% 
ethanol and centrifuged again at 15 000 x g for 20 min.  The ethanol was removed carefully and 
the DNA pellet was resuspended in 25 μL ddH2O.  DNA sequencing was carried out at the 
National Research Council (Saskatoon, Saskatchewan).  
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2.7 Active transcription assay 
2.7.1 Radiolabelling reaction 
DNAs were designed based on Pham et al. (2003) (Table 2.3).  The transcription reaction 
sequencing primer (Table 2.3) was 5'-end labeled with 32P for detection.  The concentrations of 
the reaction were as follows:  Transcription Sequencing Primer, 600 nM; T4 PNK (New England 
Biolabs), 1U; PNK Buffer (70 mM Tris-HCl, 10 mM MgCl2, and 5 mM DTT); and γ-32P ATP 
(70% labelling efficiency, 6000 Ci/mmol, 1.7 μM, Perkin-Elmer), 420 nM.  Reaction mixture 
was heated to 37°C for 1 hour and heat inactivated at 65°C for 20 min. 
2.7.2 Substrate annealing 
The double stranded transcription substrate was formed by heat annealing the transcribed 
strand to the corresponding non-transcribed strand (Table 2.3).  The annealing reaction 
concentrations were as follows:  Transcribed Strand (TTC, CCC, CTC, and AGC), 360 nM; 
Non-Transcribed Strand (TTC, CCC, CTC, and AGC), 300 nM; Heat Annealing buffer (50 nM 
Tris pH 7.5, and 50 mM NaCl).  The Transcribed Strand was annealed in excess to ensure that no 
Non-Transcribed Strand remained single stranded.  The annealing reaction mixture was heated to 
85°C and cooled gradually. 
2.7.3 Transcription reaction 
The annealed substrates were reacted with T7 RNA polymerase and Apo3 enzymes.  The 
reaction conditions were as follows:  Annealed Transcription Substrate (TTC, CCC, CTC, and 
AGC), 30 nM; T7 RNA Polymerase (Promega), 1U; ribonucleotides (rNTPs) (Promega), 500 
μM; Apo3/AID, 30-300 nM; RNase A (DNase-Free, Roche), 200 ng; Transcription Buffer (50 
mM Tris pH 7.5, 10 mM MgCl2, and 1 mM DTT).  The reaction mixture was heated to 37°C for 
60 min with samples taken at predetermined times (0 min, 5 min, 7.5 min, 10 min, 15 min, 30 
min).  The reaction was stopped by mixing phenol:chloroform:isoamyl with sample.  DNA was 
extracted using Light Phase Lock tubes (5-Prime) and washed with chloroform.  The non-
transcribed strand was then sequenced as described in section 2.7.4. 
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2.7.4 Non-transcribed strand sequencing reaction 
In this experiment, deaminations are determined by sequencing the non-transcribed strand 
of DNA and identifying any base substitutions that have occurred.  Two modified Sanger 
sequencing reactions were set up, one with ddA and a second with ddG.  The typical sequencing 
reaction involves halting the reaction at a selected dideoxynucleotide.  The sequencing requires 
that the equivalent deoxynucleotide be included in the reaction so that sequencing can continue 
through the potential stop.  In the sequencing reactions we used, the dideoxynucleotide (ddA or 
ddG) represents the only adenine or guanine. 
First the PCR master mix was set up as follows: γ-32P ATP 5'-end labeled Transcription 
sequence primer (Table 2.3), 33 nM; Transcription reaction, 10 μL; Sequenase buffer 
(Affymetrix) (26 mM Tris-HCl pH 9.5, 6.5 mM MgCl2); Thermo Sequenase DNA Polymerase 
(Affymetrix), 2 μL; ddH2O to 18 μL.  The PCR master mix was then pipette mixed and placed 
on ice.  Next, 2 thin walled PCR tubes were set up.  The ddG sequencing tube was set up as 
follows: PCR master mix, 18 μL; dC, 150μM; dA, 150 μM; dT, 150 μM; ddG, 150 μM.  The 
ddA sequencing tube was set up as follows: PCR master mix, 18 μL; dC, 150μM; dG, 150 μM; 
dT, 150 μM; ddA, 150 μM.  The PCR reaction was run with the following program: 94°C for 2 
min to denature the DNA; 94°C for 30 sec, 55°C for 45 sec, 72°C for 1 min, 6X; 4°C once 
complete. 
2.7.5 Gel electrophoresis and detection  
DNA samples were separated on 35 cm 20% PAGE sequencing gels (20% 
Acrylamide:Bis-Acrylamide 19:1, 8 M urea, 1X TBE Buffer (90 mM Tris, 90 mM Boris acid, 2 
mM EDTA pH 8.0) with 1X TBE running buffer.  The gels were pre-run for 30 min at 60W.  
Samples were heat denatured for 2 min at 85°C, then placed on ice immediately prior to loading 
into gel.  One to 3 μL of sample was loaded onto gel.  Gels were run at 60W for approximately 3 
hours, where a Xylene Cyanol dye marker has migrated approximately 27 cm.  The gel was then 
transferred to paper and dried for 2 hours with a heat/vacuum gel drier (BioRad).  Once dry, gels 
were exposed to an Imaging Screen-K (BioRad) between 0.5-12 hours depending on the activity 
of the sample. The phosphorimaging Screen was scanned using either a Typhoon Trio 
multipurpose scanner (GE Healthcare) or a Pharos FX scanner (BioRad).  
37 
 
Table 2.3 Substrates and primers used for active transcription assay. 
Name Sequence 
Transcribed Strand AGC ACC TCC TCA CCT TTC CTC TTT GCT TTC CCC 
TTT TCT CCC TAT AGT GAG TCG TAT TAT GCA 
TCT CTG 
Non-transcribed Strand AGC CAG AGA TGC ATA ATA CGA CTC ACT ATA GGG 
AGA AAA GGG GAA AGC AAA GAG GAA AGG TGA 
GGA GGT 
Non-transcribed Strand TTC CAG AGA TGC ATA ATA CGA CTC ACT ATA GGG 
AGA AAA GGG GAA TTC AAA GAG GAA AGG TGA 
GGA GGT 
Transcribed Strand TTC ACC TCC TCA CCT TTC CTC TTT GAA TTC CCC 
TTT TCT CCC TAT AGT GAG TCG TAT TAT GCA 
TCT CTG 
Non-transcribed Strand CTC CAG AGA TGC ATA ATA CGA CTC ACT ATA GGG 
AGA AAA GGG GAA CTC AAA GAG GAA AGG TGA 
GGA GGT 
Transcribed Strand CTC ACC TCC TCA CCT TTC CTC TTT GAG TTC CCC 
TTT TCT CCC TAT AGT GAG TCG TAT TAT GCA 
TCT CTG 
Non-Transcribed Strand CCC CAG AGA TGC ATA ATA CGA CTC ACT ATA GGG 
AGA AAA GGG GAA CCC AAA GAG GAA AGG TGA 
GGA GGT 
Transcribed Strand CCC ACC TCC TCA CCT TTC CTC TTT GGG TTC CCC 
TTT TCT CCC TAT AGT GAG TCG TAT TAT GCA 
TCT CTG 
Transcription Sequence Primer ACC TCC TCA CCT TTC CTC 
Substrates were designed based on experiment by Pham et al. 2003. 
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RESULTS  
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3.1 Deamination activity of Apo3A 
3.1.1 Specific Activity 
Previous to this research Apo3A had not been purified and studied biochemically.  It was 
therefore important to determine if the protein that we purified retained activity and that the 
preferred deamination motif was similar to previous reports using virus packaged Apo3A (Chen 
et al., 2006).  The assay consists of reacting an Apo3 enzyme with a synthetic DNA that contains 
two staggered cytosine motifs (Figure 3.1, sketch).  Each Apo3 enzyme has a di- or tri-nucleotide 
sequence in which it catalyzes deaminations with the greatest specific activity.  For Apo3A, the 
preferred dinucleotide sequence has been determined to be 5'TC (Chen et al., 2006).  The 
minimal motif 5'TC is conserved among most Apo3 enzymes except for Apo3G which has a 
strong preference for 5'CCC (underlined C is preferentially deaminated) (Beale et al., 2004; 
Suspene et al., 2004; Yu et al., 2004).  Substrates were analyzed in silico to ensure they would 
not form significant secondary structure.  Apo3A was found to deaminate at 5'TC sites (Table 
2.1) and we extended this observation to determine whether Apo3A has a conservative or more 
promiscuous target motif.  We determined the specific activity of the enzyme on ssDNA 
substrates (85-nt) containing 5'TTC, 5'ATC, 5'CTC, 5'GTC, or 5'ACC motifs embedded within 
the flanking 5' AAA NNN ATA that have been shown as optimal for Apo3G activity (Table 2.1) 
(Chelico et al., 2006).  Apo3A appears to deaminate all 5'TC containing sequences about equally 
and did not preferentially deaminate motifs with a specific 5'-base by more than 2-fold (Table 
3.1, specific activities of 3.1 to 6.1 pmol/µg/min).  However, there is a 100-fold decrease in 
activity when the 5'ACC sequence was used, suggesting that the dinucleotide 5'TC is necessary 
for optimal deamination activity (Table 3.1), in agreement with a previous report (Chen et al., 
2006).  Apo3A was unable to deaminate a double stranded substrate (Table 3.1).  In comparison, 
Apo3G does not have a promiscuous target motif and strictly deaminates the third C in a CCC 
motif (Beale et al., 2004; Suspene et al., 2004; Yu et al., 2004). 
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Processivity factor
5'C/3'C ratio
1.1
1.2
TTCF5' 3'15 nt 28 nt 36 ntTTC
5′ C & 3′ C
5′ C
3′ C
85 nt
48 nt
30 nt
67 nt 
B
Processivity factor
5'C/3'C ratio
3.6
3.7
CCC CCCF5' 3'15 nt 28 nt 36 nt
5′ C & 3′ C
5′ C
3′ C
85 nt
48 nt
30 nt
67 nt 
Processivity factor
5'C/3'C ratio
1.3
1.7
5′ C & 3′ C
5′ C
3′ C
60 nt
23 nt
5 nt
42 nt 
C
TTC TTCF5' 3'15 nt
3 nt
36 nt TTC TTCF5' 3'15 nt 12 nt 36 nt
D
Processivity factor
5'C/3'C ratio
Not 
determined
1.3
5′ C & 3′ C
5′ C
3′ C
69 nt
32nt
15 nt
51 nt 
TTC TTCF5' 3'15 nt 61 nt 36 nt
E
Processivity factor
5'C/3'C ratio
1.5
2.1
5′ C & 3′ C
5′ C
3′ C
118 nt
81nt
63 nt
100nt 
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Figure 3.1 Analysis of Apo3A processivity on ssDNA.  A-B, deamination experiment using a 
Fam-labeled 85 nt synthetic substrate that is specific for Apo3A (A) and Apo3G (B).  
Deaminations are detected as three bands caused by breakage at C→U lesions processed during 
the experiment.  A 5' deamination results in a 67 nt fragment, a 3' deamination results in a 48 nt 
fragment while a deamination at both motifs results in a 30 nt fragment.  C, Apo3A catalyzed 
deamination of a 60 nt Fam-labeled DNA substrate.  Deaminations result in a 5' band at 42 nt, 3' 
band at 23 nt, and a double deamination band at 5 nt.  D, Apo3A catalyzed deamination of a 69 
nt Fam-labeled DNA substrate.  Deaminations result in a 5' band at 51 nt, 3' band at 32 nt, and a 
double deamination band at 15 nt.  E, Apo3A catalyzed deamination of a 118 nt Fam-labeled 
DNA substrate.  Deaminations result in a 5' band at 100 nt, 3' band at 81 nt, and double 
deamination band at 63 nt.  Values of both processivity and 5'/3' ratio are shown below gels and 
were determined by analysis of gel band intensities.  The migration distances of the deamination 
bands were determined by allowing a reference reaction to deaminate substrate to completion.  
Sketches above gel pictures depict DNA substrates utilized.  Results are averaged from at least 
two independent trials.  The standard deviation (A and B) or the range (C and E) for the 
processivity factors are: 0.25 (A), 0.09 (B), 0.46 (C), and 0.57 (E).  For (D), a deamination at 
both motifs could not be detected and precluded the calculation of a processivity factor.  Figure 
is adapted from Love et al. 2012. 
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Table 3.1 Specific activities of Apo3A, Apo3H, and Apo3G on ssDNA substrates.  Specific 
activities were determined by measuring pmoles of substrate deaminated per min for a 
microgram of enzyme.  Values are shown ± the SD determined from three (Apo3A, Apo3G) or 
the range of 2 (Apo3H) independent experiments.  The ds indicates double-stranded DNA. 
Enzyme    Sequence  Specific Activity 
(pmol/min/μg) 
Apo3A   
 
 
 
 
(ds) 
aaa ACC ata 
aaa ATC ata 
aaa TTC ata 
aaa CTC ata 
aaa GTC ata 
aaa TTC ata 
0.07 ± 0.01 
4.6 ± 1.5 
6.1 ± 1.9 
4.1 ± 2.5 
3.1 ± 2.5 
Undetectable 
Apo3H   aaa CTC ata 
aaa ATC ata 
aaa TTC ata 
aaa GTC ata 
aaa ACC ata 
8.2 ± 1.0 
1.9 ± 0.3 
2.4 ± 1.0 
2.1 ± 1.6 
Undetectable 
Apo3G   aaa CCC ata 21.3 ± 0.9 
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3.1.2 Processivity 
Apo3G was shown to deaminate cytosines processively using a 3-dimensional search that 
is characteristic of facilitated diffusion (Chelico et al., 2006; Feng and Chelico, 2011; Halford 
and Marko, 2004).  In this type of processive movement, the enzyme can slide and make 
microscopic dissociations and reassociations with the DNA (termed hopping, jumping or 
intersegmental transfer), without diffusing into the bulk solution, in order to efficiently search for 
target sequences where catalysis takes place (Chelico et al., 2006; Feng and Chelico, 2011; 
Halford and Marko, 2004).  Apo3G has also been shown to prefer deamination towards the 5'-
end of linear ssDNA (Figure 3.1 B) (Chelico et al., 2010; Chelico et al., 2008; Senavirathne et 
al., 2012).  Apo3G can move on ssDNA in both the 5’ and 3’ direction, but can only catalyze 
deamination approaching a 5’CCC motif from 3’ to 5’.  This has been termed a catalytic 
orientation specificity (Chelico et al., 2006).  It is not known if these hallmark features of Apo3G 
are unique or found in other Apo3 family members.  Here Apo3G is used as a control for Apo3 
activity as many of its biochemical characteristics have been determined.  As will become clear 
throughout the presentation of our work, Apo3G is unique within the Apo3 family. 
Substrates used to determine processive characteristics of Apo3A contain two 
deamination motifs separated by a given distance and contain a Fam-labeled thymine in between 
the two deamination motifs.  The internal Fam-label allows identification of deaminations that 
occurred at both 5'TTC motifs on the same ssDNA substrate. All deamination reactions were 
performed under ‘single hit’ conditions (<15% substrate usage) (Creighton et al., 1995).  Single 
hit conditions were determined from research performed with polymerases that determined that 
when less than 15% of a given template is extended, each of the extended products is the result 
of a single interacting polymerase with the substrate (Creighton et al., 1995).  As the percentage 
of templates extended increases, the likelihood that more than one polymerase catalyzed the 
extension reaction is also increased.   
To study Apo3A, we used a substrate with two 5'TTC motifs separated by 28-nt (Figure 
3.1 A, sketch).  The specific activities for Apo3A and Apo3G on these substrates were 6.1 
pmol/min/μg and 21.3 pmol/min/μg, respectively (Table 3.1).  On this substrate, Apo3A did not 
catalyze the deamination of both sites processively as seen with the processivity factor of 1.1 
(Figure 3.1 A, below gel).  The processivity factor is a ratio of the observed double deaminations 
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(Figure 3.1 A, 5'C & 3'C band) to the calculated expected value if the double deaminations were 
from independent events of two enzymes, i.e., not processive.  Therefore, a processivity factor of 
1 indicates that the two deaminations on the substrate occurred by independent events. 
Importantly, if deaminations were allowed to take place outside of single-hit conditions (>15% 
substrate usage), then double deamination events were clearly seen on the gel indicating that the 
substrate can be acted upon by Apo3A in two independent events and be deaminated to near 
completion (data not shown). Apo3A also does not show a preference for deamination of either 
the 3'- or 5'-proximal motif (Figure 3.1 A, 5'C/3'C ratio is 1.2). The processive enzyme Apo3G 
demonstrates very different deamination characteristics on its cognate substrate (Figure 3.1 B). 
Apo3G has a processivity factor of 3.6 (Figure 3.1B, below gel). This means that Apo3G is ~4-
fold more likely to catalyze a processive deamination of two 5'CCC motifs than deaminate each 
motif in a separate enzyme-substrate encounter. Apo3G also shows a characteristic preference 
for deamination of cytosine motifs at the 5'-end (Figure 3.1 B, 5'C/3'C ratio is 3.7-fold) (Chelico 
et al., 2006).  
To determine whether Apo3A could deaminate C residues processively if the distance 
between the 5'TTC motifs was changed, we tested substrates that had either a 3- or 12-nt distance 
between deamination motifs (Figure 3.1 C-D). For the substrates with the 5'TTC motifs 3-nt 
apart, Apo3A had a low processivity (Figure 3.1 C, processivity factor 1.3), suggesting that 
minimal local scanning can take place. However, when the substrate had the 5'TTC motifs 12-nt 
apart, Apo3A did not catalyze processive deaminations as demonstrated by no double 
deamination band being detectable under single-hit conditions, which precluded the calculation 
of a processivity factor (Figure 3.1 D, absence of 5'C & 3'C band).  To ensure that a double 
deamination was possible for the 12 nt substrate, Apo3A was reacted with the substrate until a 
band could be visualized (>15% substrate usage) (data not shown).  Based on data from a mutant 
Apo3G that prefers to jump more than slide, the jumping movement appears to favor 
deamination motifs that are spaced further apart (Feng and Chelico, 2011). On a substrate with 
the 5'TTC motifs separated by 61 nt, Apo3A demonstrates a processivity factor of 1.5 and a 
polarity preference of 2.1 for the 5'-proximal C (Figure 3.1 E). That the processivity factor is 
above 1 for this substrate indicates that Apo3A may be able to catalyze processive deaminations 
of distantly spaced cytosines (>30 nt) a small proportion of the time (Figure 3.1 E). All together 
the data (Figure 3.1 A, C-D) indicate that Apo3A has a limited ability for local sliding (Figure 
45 
 
3.1 C) and distal jumping (Figure 3.1 E), suggesting that the large majority of deaminations 
catalyzed by Apo3A are non-processive. 
3.2 Deamination activity of Apo3H 
To address the evolutionary pressure on Apo3H that had caused its inactivation, we 
developed two hypotheses.  Either the Apo3H activity had become too great and was resulting in 
cellular DNA damage, or that the activity had been lost to the point where the enzyme was 
essentially useless against retroelement restriction.  We used a biochemical approach to 
determine the inherent properties of the enzyme, which could provide evidence for the 
“incorrect” function or loss of function of Apo3H in comparison to other APOBEC enzymes. 
We used the deamination assay to determine if the activity of Apo3H was different from 
other Apo3 family members. The system consisted of an 85 nt substrate with staggered cytosine 
motifs (Figure 3.2 A, sketch).  A variety of substrates were used to determine the motif with the 
highest specific activity (Table 3.1).  The 5'CTC motif resulted in the highest activity and was 
used in all subsequent experiments (Table 3.1). The activity of Apo3H (8.2 pmol/μg/min) was 
25% higher than Apo3A (6.1 pmol/μg/min), but lower than Apo3G (21.3 pmol/μg/min) (Table 
3.1).  This addressed the initial hypothesis that evolutionary pressure on Apo3H may be due in 
part to its proficiency in catalyzing deaminations.  Second, the first deamination experiment 
demonstrated that Apo3H was able to catalyze deaminations in a processive manner (Figure 3.2 
A, below gel).  Previously it has been demonstrated that the non-catalytic domain of Apo3G was 
necessary for processivity (Chelico et al., 2010).  This is thought to be necessary because the 
Apo3G catalytic domain is negatively charged and requires the positively charged N-terminal 
domain to stay associated with ssDNA (Chelico et al., 2010).  Apo3H does not possess a second 
inactive domain to mediate processivity as does Apo3G (Chelico et al., 2010).  It has however, a 
high positive charge that may allow it to bind tightly to DNA (addressed in Section 3.4). 
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Figure 3.2 Analysis of Apo3H processivity on ssDNA.  A, deamination experiment using a 
Fam-labeled 85 nt DNA synthetic substrate that is specific for Apo3H (CTC motif).  
Deaminations are detected as three bands caused by breakage at C→U lesions catalyzed during 
the experiment.  A 5'C deamination results in a 67 nt fragment, a 3'C deamination results in a 48 
nt fragment while a deamination at both motifs results in a 30 nt fragment.  B, Apo3H catalyzed 
deamination of an 85 nt Fam-labeled DNA substrate.  Deaminations results in a 3'C band at 72 
nt, 5'C band at 46 nt, and double deamination band at 30 nt.  C, Apo3H catalyzed deamination of 
a 118 nt Fam-labeled DNA substrate.  Deaminations result in a 5'C band at 100 nt, 3'C band at 81 
nt, and double deamination band at 63 nt.  D, Apo3H catalyzed deamination of a 118 nt Fam-
labeled DNA substrate as in C, but with a 20 nt DNA spacer (blue) annealed between cytosine 
motifs.  Values of both processivity and 5'C/3'C ratio are shown below gels and were determined 
by analysis of gel band intensities.  The migration distances of the deamination bands were 
determined by allowing a reference reaction to deaminate substrate to completion.  Sketches 
above gel pictures depict DNA substrates utilized.  DNA samples were heat denatured (2 min at 
85°C) prior to loading and were separated under denaturing conditions.  Results are averaged 
from at least two independent trials.  The standard deviation (A) or range (B, C, and D) of 
processivity values are: 0.42 (A), 0.01 (B), 2.55 (C), and 0.28 (D). 
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3.2.1 Polarity 
Apo3H also demonstrated a notable bias towards the 3'C motif of the DNA (Figure 3.2 A, 
5'C/3'C ratio 0.7).  This stood out as uncharacteristic for an Apo3 enzyme based on the data 
obtained for Apo3G which shows a strong 5'C motif bias (Figure 3.1 B, 5'C/3'C ratio 3.7), as 
well as the data obtained for Apo3A where there was little 5'-bias (Figure 3.1 A, 5'C/3'C ratio 
1.2).  We investigated the directional bias of Apo3H by creating a substrate that had the cytosine 
motifs in a reversed orientation (Figure 3.2 A and B, compare substrate sketches).  In this way, 
we could see either that the bias towards the 3' end of the DNA was retained, or that the 
directional bias was due to a preference of the enzyme to deaminate motifs flanked by a greater 
number of nucleotides i.e., motifs closer to the centre of the ssDNA.  It was found that Apo3H 
retained its preference for the 3'-end of the ssDNA, but that because the motif had been moved 
closer to the centre of the DNA there was a increase in 5'C deamination (Figure 3.2 A-B, 
compare 5'C/3'C ratios 0.7 to 0.9).  These data suggest that Apo3H can catalyze a deamination 
reaction if there is a greater amount of ssDNA flanking the 5'-end of the motif.  This appears to 
be the opposite of Apo3G which required more ssDNA flanking the 3'-end of the motif (Chelico 
et al., 2008). 
3.2.2 Processivity 
We investigated the ability of Apo3H to catalyze processive deaminations using various 
custom substrates.  On a substrate with the CTC motifs separated by 28 nt, Apo3H demonstrated 
the strongest processivity (Figure 3.2 A, below gel, processivity factor 5.5) in comparison to 
Apo3A (Figure 3.1 A, below gel, processivity factor 1.1) or Apo3G (Figure 3.1 B, below gel, 
processivity factor 3.6).  We tried increasing the distance between the cytosine motifs to 61 nt 
and observed a processivity factor of 5.2 (Figure 3.2 C).  Previous research using Apo3G 
processivity mutants has demonstrated that increasing the distance between two cytosine motifs 
for an enzyme that prefers to slide results in a reduction in the processivity (Chelico et al., 2006; 
Feng and Chelico, 2011).  This is because Apo3G uses two different mechanisms for scanning 
DNA, both a sliding motion where Apo3G scans every nucleotide and a jumping motion in 
which microscopic dissociations allow translocations of >20 nt (Feng and Chelico, 2011).  In the 
case of Apo3H, the jumping motion is likely part of the method of scanning employed because 
no loss in processivity is observed.  To determine whether sliding was also involved, we 
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challenged Apo3H processivity to observe if it was reduced by an experimental block of any 
potential sliding movements of Apo3H.  We introduced a DNA block that annealed to the 
substrate DNA between the cytosine motifs (Figure 3.2 D, sketch), which has been shown to 
block the sliding component of Apo3G (Chelico et al., 2006).  We found that there was ~2-fold 
reduction in the processivity when the dsDNA block was annealed (Figure 3.2 C, compare 2.1 
from 5.2), indicating that Apo3H does use sliding for scanning DNA in combination with 
jumping.  To quantify the contribution of sliding versus jumping we compared the ratio of 
successful coordinated deaminations i.e. if Apo3H deaminates the 5'-end motif and proceeds to 
deaminate the 3'-end motif in a single interaction for both the fully ssDNA substrate (Figure 3.2 
C) and the partially dsDNA substrate (Figure 3.2 D).  To do this, we compared the ratio of 
(5'C&3'C)/5'C deaminations of fully ssDNA and found that Apo3H successfully deaminates both 
C targets at a frequency of 0.89 (Figure 3.2 C).  When a DNA block is introduced the ratio of 
successful processive deaminations is reduced to a frequency of 0.13 as calculated by the 
(5'C&3'C)/5'C ratio.  This means that jumping contributes to 15% of the total processive 
movement (0.13/0.89) and sliding contributes to 85% of the movement.  In contrast Apo3G has 
been found to use jumping 60% of the time and sliding 40% of the time (Feng and Chelico, 
2011).  
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3.3 Apo3A weakly binds ssDNA 
Based on the deamination data (Figure 3.1 A, C-E) that Apo3A was not able to catalyze 
processive deaminations with great efficiency, we hypothesized that this could be due to poor 
DNA binding properties.  We selected Apo3G as a control based on its ability to deaminate 
processively (Figure 3.1B and (Chelico et al., 2006)) as well as reports found in the literature 
that have measured its affinity for ssDNA (Chelico et al., 2006; Iwatani et al., 2006). 
Rotational anisotropy was used to determine the apparent dissociation constant (Kd) of 
Apo3A, Apo3H, and Apo3G to a single stranded DNA substrate.  Rotational anisotropy is the 
measure of the change in polarization of emitted light from a fluorophore that has been excited 
by vertically polarized light. The change in polarization is dependent on the rotational speed of 
the labeled molecule.  Molecules with increased mass tumble more slowly than molecules with 
less mass.  Therefore if a binding partner interacts with the fluorescently labeled molecule e.g. 
DNA, there will be a decrease in the change of the polarization state. 
It was determined that Apo3A had an apparent Kd of 9.2 μM compared to 0.14 μM for 
Apo3G (Figure 3.3).  Apo3A was not able to effectively bind to ssDNA, likely due to its 
predicted charge of -2.5 at a pH of 7.4. Both Apo3A and Apo3G binding curves were fit to a Hill 
sigmoidal curve indicating that cooperative binding or oligomerization may be occurring (Figure 
3.3).  This indicates that Apo3G binds to DNA 65-fold tighter than Apo3A.  These findings 
suggest that the inability of Apo3A to catalyze processive deaminations is in part due to its 
inability to bind tightly to DNA. To better characterize the interaction of Apo3H with DNA, we 
sought to determine its apparent Kd when binding ssDNA by rotational anisotropy.  Binding of 
Apo3H to ssDNA demonstrated a Kd of 0.19 μM and fit a Hill sigmoidal curve (Figure 3.3 B), 
which is similar to Apo3G (apparent Kd of 0.14 μM, Figure 3.3 C).  The deamination data 
obtained previously (Figures 3.1 B and 3.2 A) showed approximately a 1.5-fold greater 
processivity for Apo3H compared to Apo3G, however the apparent Kd values are similar (Figure 
3.3 B-C).  It may indicate that ssDNA binding strength alone is not the only indicator of 
processivity. There are likely other variables that determine processivity based on amino acids 
that contact the DNA, which is likely to differ between Apo3G and Apo3H that are Z2 and Z3 
deaminases, respectively (Figure 1.3). 
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Figure 3.3 Apparent dissociation constant of Apo3A, Apo3H, and Apo3G for ssDNA.  
Binding of Apo3A (A), Apo3H (B) or Apo3G (C) to ssDNA was determined using fluorescence 
depolarization (rotational anisotropy).  Error bars represent the standard deviation of three 
independent experiments.  The standard deviations of the Kd are (A) ± 2.5 μM, (B) ± 0.02 μM, 
and (C) ± 0.02.  Figure is adapted from Love et al. 2012 (Love et al., 2012). 
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3.4 Oligomerization state of Apo3A and Apo3G 
Apo3A rotational anisotropy ssDNA binding data was best fit to a sigmoid regression 
curve.  A sigmoidal relationship indicates that there is cooperative binding of the substrate.  We 
used multi-angle light scattering (MALS) to determine the molecular weight and therefore the 
oligomerization states of Apo3A and Apo3G.  MALS involves in-line analysis of protein eluted 
from a size exclusion column by 18 lasers at different angles and a refractive index detector.  The 
amount of light scattering is measured and the resulting Raleigh ratio can be used to determine 
the absolute molecular mass of the molecule (Wyatt, 1993).  Apo3A was found to be a monomer 
(25 kDa) in 97% of the elution.  In 3% of the elution there is a distinct dimer peak (53 kDa).  The 
MALS demonstrates that oligomers can occur (Figure 3.5 A, 3%), but are not favorable in 
solution.  This is consistent with the binding analysis of Apo3A (Figure 3.5 A) which suggested 
that oligomerization (cooperation) could be associated with DNA binding. 
Apo3G was analyzed in sequence with Apo3A but demonstrated more diversity in 
oligomerization states.  Apo3G was found to mostly elute as dimers (41%, 126 kDa) and 
tetramers (47%, 284 kDa).  Monomeric Apo3G was found in 11% of the elution (46 kDa). 
We also wished to test the oligomerization state of Apo3H but we were unable to reach 
the concentrations of enzyme required for the assay, approximately 1 mg/mL.  We are currently 
in the process of optimizing the use of a cation exchange column to increase the concentration of 
Apo3H for MALS. 
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Figure 3.4 Determination of molecular mass of Apo3A and Apo3G using multi-angle light 
scattering.  Purified Apo3A was resolved by size-exclusion chromatography in running buffer 
with 150 mM NaCl and 50 mM HEPES pH 7.3. The molecular mass is plotted throughout the 
eluted peaks (line plot, left y-axis). The Rayleigh light scattering chromatogram shows the 
protein distribution and is plotted on the right y-axis. The median molecular masses and 
distributions for Apo3A are 97% monomers (25 kDa) and 3% dimers (53 kDa).  The median 
molecular masses and distributions for Apo3G are 47% tetramers (284 kDa), and 41% dimers 
(126 kDa), and 11% monomers (46 kDa). 
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3.5 Efficiency of HIV restriction 
3.5.1 Mutational spectra induced by Apo3A, Apo3H, and Apo3G 
The (-)DNA generated by RT during, HIV reverse transcription, is a target for Apo3-
deamination (Yu et al., 2004).  It has been demonstrated that Δvif HIV is unable to produce 
infectious virions after exiting a cell line that is expressing Apo3G (Sheehy et al., 2002).  The 
role that Apo3A and Apo3H play in the restriction of HIV has not been definitively explained.  
Apo3A has been shown to have strong restriction capability on HIV in myeloid cells (Berger et 
al., 2011), but the mechanism is not known (Peng et al., 2007).  Apo3H has also been 
demonstrated to have HIV restriction ability in some studies (Harari et al., 2009; OhAinle et al., 
2008; Tan et al., 2009), and has partial resistance to Vif-mediated degradation (unpublished data) 
(OhAinle et al., 2008; Tan et al., 2009).  To determine the potential role of Apo3A and Apo3H 
in restriction of HIV replication, we used a reconstituted HIV reverse transcription system (See 
Materials and Methods).  For comparison, Apo3G was also tested in this system. 
The reverse transcription system used here consisted of a 368 nt synthetic RNA that 
contained the following keys features: a primer to initiate (-)DNA synthesis; PPT, necessary for 
priming the elongation of the (+)DNA of the model provirus; a lacZα reporter gene, to determine 
mutated clones from those sustaining no mutations and; 120 nt of the prot gene from HIV-1, 
because it is well characterized and a complete mutagenesis study (Loeb et al., 1989) can be used 
for reference when analyzing the consequences of Apo3 deaminations on the coding sequence.  
The reaction is started by the addition of dNTPs to a reaction mixture containing HIV-1 reverse 
transcriptase, nucleocapsid, and the synthetic RNA genome in the presence or absence of an 
Apo3 enzyme.  An important feature of the system is the PPT which enables (+)DNA synthesis 
to occur as in HIV proviral DNA synthesis or HIV replication.  The (+)DNA synthesis can only 
begin after the RNaseH domain of RT degrades the viral genomic RNA, therefore regions 
furthest from the PPT (the LacZα region) are single stranded the longest time and expected to 
incur more deaminations. 
Based on Apo3G literature, processivity has been predicted to play a strong role in its 
ability to catalyze large numbers of deaminations because partially processive Apo3G mutants 
induced fewer mutations during reverse transcription (Feng and Chelico, 2011).  However this 
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has not been assessed by comparison to a non-processive enzyme.  From the results of the 
deamination assays discussed earlier, we knew that Apo3A was weakly processive (Figure 3.1 A, 
C-E).  We predicted that we would see many white colonies as a result of the high amount of 
dissociation and reassociations events of Apo3A, but that each of the clones would carry fewer 
mutations when compared to Apo3G.  For Apo3G we expected many white colonies due to a 
bimodal off rate from DNA involving short and long binders (Chelico et al., 2008) with each 
clone containing many mutations due to processive scanning.  We found that the frequency of 
white/light blue colonies was 0.86 for Apo3A and 0.90 for Apo3G.  This number was 
approximately 9-fold greater than the level of mutation induced by the reverse transcription 
system in the absence of an Apo3 enzyme (0.10). 
To compare the mutations induced by Apo3A, Apo3H, and Apo3G a mutational spectra 
was used (Figure 3.5).  From the mutational spectra data observed for Apo3A and Apo3G, it can 
be seen that there were a high number of mutations induced by each enzyme (Figure 3.5) and 
processivity may not be essential.  Apo3H was able to catalyze deaminations at a similar number 
of sites (Apo3H, 44 sites) when compared to Apo3A (44 sites) and Apo3G (41 sites), but the 
most highly mutated sites were lower for Apo3H (compare Figure 3.5 A-C, most mutated site 
Apo3A 88%, Apo3H 60%, Apo3G 92%).  Upon analysis of the spectrum of mutations induced 
by Apo3H, it can be seen that the highest percentage of “hot spots”, highly deaminated sites, are 
seen in the lacZα region.  The ratio of intensities between the most deaminated site in the lacZα 
and the most deaminated site in the prot is 1.5 for Apo3H, while the ratio for Apo3A is 1.7 and 
Apo3G is 1.9.  These data indicate each specific activity and processivity play a role in Apo3 
deamination kinetics and that a strong ability in one of the attributes may be able to compensate 
for another. 
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Figure 3.5 Apo3A-, Apo3H-, and Apo3G-induced mutational spectra.  Spectra of G→A 
mutations resulting from Apo3A- (A), Apo3H- (B), and Apo3G-catalyzed (C) deaminations 
occurring during reverse transcription by HIV-1 reverse transcriptase.  The DNA substrate 
formed contains 120 nt of the HIV-1 protease (prot) gene (nt 2282-2401) and 248 nt of the lacZα 
reporter sequence.  Data is represented as the percentage of clones containing the mutation at the 
indicated position.  The x-axis denotes the position of the mutation in the construct.  Figure is 
adapted from Love et al. 2012. 
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3.5.2 Mutations per clone induced by Apo3A, Apo3H, and Apo3G 
The spectra results discussed thus far only reveal part of the differences between these 
three Apo3 proteins.  We further categorized the mutated sequences selected from the 
reconstituted HIV reverse transcription assay based on the different numbers of mutation, 
sustained on a per clone basis.  It was seen that in the prot sequence, Apo3G was able to mutate 
clones the greatest number of times with 28% of mutated clones having greater than 3 mutations 
compared to Apo3A and Apo3H which had only 16% and 8% of clones with greater than 3 
mutations, respectively (Figure 3.6 A-B).  The kinetics of reverse transcription is such that the 
substrate for Apo3-mediated deamination is revealed by RNaseH activity randomly but the time 
that ssDNA regions are vulnerable to deamination depends on the proximity to the PPT (See 
Section 1.2 and Figure 1.2).  Since the prot region is adjacent to the PPT (Figure 2.2), it is single-
stranded for the shortest time relative to the lacZα region. 
The difference between clones generated by Apo3A, Apo3H, and Apo3G are less 
pronounced in the lacZα region.  This region is available for a longer period of time for 
deamination, so a greater number of mutations are expected for all Apo3 enzymes.  Most clones 
produced by the Apo3 enzymes contained 4-5 mutations (Apo3G 24%, Apo3A 32%, and Apo3H 
48%).  At the high end the mutational load, both Apo3G and Apo3A had 4% of the clones with 
between 14 and 15 mutations.  Sixteen percent of Apo3G mutated clones sustained between 12 
and 13 mutations.  Apo3H was not able to cause greater than 11 mutations in any clones in this 
system.  The inability of Apo3H to catalyze large numbers of mutations per clone could be due 
to its preferential bias to deaminate near the 3'-end of DNA (Figure 3.2) rather than the 5'-end of 
DNA that is single-stranded the longest. Alternatively, different distribution of jumping and 
sliding events for Apo3H in comparison to Apo3G, could lead to inefficient scanning of the 
substrate (Figure 3.5 B).  
It is unexpected that a non-processive enzyme (Apo3A) could induce so many 
deaminations in this system. However, the timing of reverse transcription must be slow enough 
to allow multiple interactions of Apo3A with the (-)DNA in the lacZα to induce numerous 
deaminations (Figure 3.6 B). Yet, this inefficiency is evident in the prot region that is single 
stranded for a shorter time where Apo3A deaminations per clone are less than Apo3G (Figure 
3.6 A). Since Apo3H also appears to have a deficiency with respect to the numbers of mutations 
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per clone, compared to Apo3G (Figure 3.5 and 3.6), it is possible that there is a different 
distribution of jumping and sliding events (Section 3.2.2) for Apo3H and Apo3G results in their 
differential ability to induce mutations (Figure 3.5). 
  
61 
 
 
Figure 3.6 Apo3A-, Apo3H-, and Apo3G-induced mutations per clone.  Plots which illustrate 
the per clone numbers of G→A mutations that can be obtained in the prot (A) or lacZα (B) 
induced by Apo3A (●), Apo3H (●), and Apo3G (●) deaminations.  Values were binned for 
analysis and the bin range is shown on the x-axis.  Figure is adapted from Love et al. 2012.
A
B
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3.5.3 Analysis of mutated amino acids and protease activity 
To determine the effectiveness of an Apo3 enzyme to functionally inactivate HIV, we 
analyzed the results of the mutations incurred in the prot region of the reverse transcript. The 
number of mutations sustained by a given clone has been shown as a good indicator of how 
effective an Apo3 enzyme will be in successfully inactivating an HIV provirus (Harris et al., 
2003; Mangeat et al., 2003; Zhang et al., 2003).  In a study by Loeb et al.  each of the amino 
acids of the protease active site were substituted and tested for activity (Loeb et al., 1989).  Loeb 
et al. found that a single amino acid change in the protease active site was sufficient to eliminate 
its activity.  We used the Loeb et al. study to compare the resulting amino acid changes in the 
mutated clones.  It was observed that protease genes mutated by Apo3A were predicted to 
remain active 56% of the time (Table 3.2), both because both the number of mutations was not 
high enough to cause inactivation and the codon substitutions were silent or did not change 
protease activity.  The specific amino acid changes that Apo3A catalyzed most often were M46I 
(52%), D35N (28%), and D30N (24%) (Table 3.2), where each of those mutations had no affect 
on protease activity (Table 3.2).  Furthermore, M46I and D30N both conferred the protease with 
drug resistance as revealed by cross-referencing the mutations with the Stanford HIV Drug 
Resistance Database.  Apo3H did not deaminate any site greater than 36% demonstrating that 
deaminations catalyzed by this enzyme are more random in nature than the other two Apo3 
enzymes tested here (Table 3.2).  The top three amino acid substitutions observed for Apo3H 
were W42STOP (36%), M46I (20%), and D35N (16%) (Table 3.2).  Only W42STOP abolished 
protease activity of the top three amino acids hit by Apo3H.  Like Apo3A, Apo3H caused the 
substitution of M46I which conveys drug resistance.  The top four mutations found in clones 
mutated by Apo3G were G52S (48%), G51R/E (36%), and D25N (32%).  Both G52S and 
G51R/E lead to an inactivation of the protease (Table 3.2).  Apo3G also did not cause amino acid 
substitutions that resulted in protease inhibitor drug resistance with a high efficiency (M46I 4%, 
and D30N 8%) (Table 3.2).   
We summarized the amino acid substitution data by looking at each clone individually to 
determine the predicted activity of the protease.  Here Apo3G was by far the best at inactivating 
the protease with 72% of the clones coding for an inactive protease, as most of the clones 
sustained greater number of mutations and those amino acid changes most often eliminated the 
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activity of the protease (Figure 3.8).  Apo3H was able to cause inactivation of the protease in 
60% of clones and Apo3A was only able to inactivate 36% of clones sequenced (Figure 3.8).  
Interestingly, in the protease region, Apo3A was the most efficient at causing a deamination at 
least once in all of the clones (no mutation 12% for Apo3A, compare 20% for Apo3H and 
Apo3G) suggesting that non-processive enzymes do interact with more substrate molecules than 
processive enzymes. 
Taken together, these results indicate that the types of mutations that are sustained by a 
target sequence can be just as important as the number of mutations.  Apo3G, which deaminates 
5’ CCC motifs, had a high level of induced mutagenesis and inactivation (Figure 3.1 B). 
However, when sparsely mutated clones were examined from Apo3G experiments we found that 
in the majority of cases, 1 mutation was sufficient for inactivation of protease.  This is in contrast 
to Apo3A and Apo3H which deaminate cytosine in 5'TTC and 5'CTC motifs, respectively, and 
did not cause high levels of protease inactivation (Table 3.2), despite some clones with high 
numbers of mutations (Figure 3.6-7). As a result, Apo3A and Apo3H were unable to benefit the 
“host” of this scenario due to inducing a number of non-inactivating mutations in the protease.  
Importantly, the deamination motif preference was recapitulated from data on ssDNA (Figure 3.1 
A-B and 3.2 A) where the single domain Apo3 enzymes have a greater specific activity on the 
minimum sequence cytosine motif 5'TC while Apo3G has a preference for 5'CC. 
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Table 3.2 Amino acid changes in the HIV-1 protease induced by deaminations by Apo3A, 
Apo3H, and Apo3G.  Protease enzyme activity was inferred from a complete mutagenesis study 
performed by Loeb et al. (Loeb et al., 1989).  Plus (+) indicates that the protease would remain 
active or partially active given the substitution.  Negative (-) indicates that protease activity 
would be decreased.  The Stanford HIV Drug Resistance Database was consulted to determine if 
a given amino acid substitution would cause resistance.  Resistance is indicated by “Yes”. 
Protease 
amino acid 
position 
Nucleotide 
change 
(underlined) 
 
Amino acid 
change 
Protease 
enzyme 
activity 
Protease 
inhibitor 
resistance 
 
Mutated clones (%) 
Apo3G  Apo3A  Apo3H
19  CTG→CTA  L→L +     8
21  GAA→AAA  E→K +   4  8
25  GAT→AAT  D→N + 32  4  12
27  GGA→GAA 
GGA→AGA 
G→E
G→R 
‐
‐   
4 
16 
8 
 
12
 
29  GAT→AAT  D→N ‐   8  12
30  GAT→AAT  D→N + Yes 8  24  12
34  GAA→AAA  E→K + 4  20  8
35  GAT→AAT  D→N + 4  28  16
40  GGG→GGA 
GGG→GAG 
GGG→AGG 
GGG→AAG 
G→G
G→E 
G→R 
G→K 
+
‐ 
‐ 
‐ 
 
 
 
 
8 
8 
8 
4 
 
 
 
 
 
 
42  TGG→TAG 
TGG→TGA 
TGG→TAA 
W→STOP
W→STOP 
W→STOP 
‐
‐ 
‐ 
 
 
16 
 
 
4 
8 
 
36 
4 
46  ATG→ATA  M→I + Yes 4  52  20
48  GGG→AGG 
GGG→GGA 
G→R
G→G 
+
+   
16 
4 
 
   
49  GGA→AGA 
GGA→GAA 
GGA→AAA 
G→R
G→E 
G→K 
‐
‐ 
‐ 
 
 
8 
 
 
 
 
 
4 
4 
51  GGA→AAA 
GGA→GAA 
GGA→AGA 
G→K
G→E 
G→R 
‐
‐ 
‐ 
 
 
4 
 
32 
16 
4 
 
12 
 
52  GGT→AGT  G→S ‐ 48   
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Figure 3.7 Predicted HIV-1 protease activity effects after Apo3A-, Apo3H-, and Apo3G-
induced mutagenesis.  Each prot region sequenced was analyzed individually to determine 
whether deaminations catalyzed by Apo3A (A), Apo3H (B), and Apo3G (C) were able to induce 
mutations that led to prot inactivation (inactive), no inactivation (active), or no mutations.  A, 
Apo3A was able to inactivate the prot in 36% of the clones, 12% sustained no mutations, and 
52% of clones sustained mutations but remained active.  B, Apo3H was able to inactivate the 
prot in 60% of clones, 20% did not have any mutations, and 20% of clones sustained mutations 
but remained active.  C, Apo3G was able to inactivate the prot in 72% of the clones, 20% 
sustained no mutations, and only 8% of the clones sustained mutations and remained active.  
Figure is adapted from Love et al. 2012.  
A B
C
Apo3A Apo3H
Apo3G
Active
Inactive
No 
Mutation
No 
Mutation
No 
Mutation
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3.6 Deamination during active transcription 
Apo3 enzymes can be dangerous for the host cell DNA since they can initiate 
mutagenesis.  The best studied Apo3 enzyme, Apo3G, is found in the cytoplasm in all cell types 
and is only found in the nucleus when the cell has been irradiated (Nowarski et al., 2012).  The 
single domain Apo3 enzymes, Apo3A and Apo3H, are found in both the nucleus and the 
cytoplasm (Chen et al., 2006; OhAinle et al., 2008).  Nuclear host DNA can become temporarily 
single stranded when it is being replicated or transcribed.  Genes that are transcribed often pose a 
greater risk of sustaining deaminations by Apo3 type activity as demonstrated by AID (see 
Section 1.3.4).  In particular there is evidence emerging that AID actually interacts with the 
entirety of the transcribed genome in B cells and would severely damage the host chromosome if 
it were not for robust DNA repair correcting deaminations in an ongoing process (Hasham et al., 
2010). 
To test if Apo3A and Apo3H could deaminate during active transcription, we used an 
experimental system that had been used previously to demonstrate the activity of AID during 
transcription (Pham et al., 2003). The experiment consisted of designing a double stranded 
substrate that contained a T7 promoter sequence upstream of a cytosine deamination motif on the 
non-transcribed strand specific for Apo3A, Apo3H, Apo3G, or AID. The non-transcribed strand 
is thought to be the substrate for AID within the transcription bubble (Perlot et al., 2008; Pham et 
al., 2003). Deamination of the cytosine motif can only occur if the T7 RNA polymerase is able to 
open the double stranded substrate to expose a single stranded deamination motif (data not 
shown).  To detect any nucleotide changes that may have occurred, we sequenced the non-
transcribed strand.  We set up two modified Sanger sequencing reactions in which either ddA or 
ddG made up the total A or G in the reaction.  This was done to observe the presence of a uracil 
in the non-transcribed strand directly (ddA) by causing sequence termination at that spot or 
indirectly by observing sequencing pass through (ddG). 
To directly detect the uracil in the DNA substrate, we set up a dideoxynucleotide 
sequencing reaction where dG, dC, and dT were present and ddA represented the only adenine 
available.  In this way, we would observe a complete stop of all sequenced templates where an A 
was required for continued synthesis.  This would occur if the cytosine were deaminated in 100% 
of the sequences.  In the negative control, we observed a complete stop at the first T of the non-
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transcribed strand, which is located downstream from the deamination motif (Figure 3.8 A, DNA 
only).  For AID, we observed a stop band in the ddA lane at what was the C position in the DNA 
sequence, indicating that deamination of the C→U had taken place (Figure 3.8 A, AID ddA 
lane).  At this time point not all of the cytosines are converted to uracils (Figure 3.8 B, 30 min) 
so we observe sequencing pass through, indicating no deamination (Figure 3.8 A, downstream T 
has stop band).  The ratio of integrated gel band intensity between the deaminated and un-
deaminated bands was compared to determine the amount of substrate usage.  For Apo3A and 
Apo3H we observed a strong stop band at the location of the cytosine (Figure 3.8 A, Apo3A and 
Apo3H).  To accommodate the specific requirements of Apo3A and Apo3H sequence preference, 
there had to be a T incorporated early in the non-transcribed strand only 1 nt away from the 
target C (Figure 3.8 A, Apo3A and Apo3H).  We were still able to detect the difference in size 
between these extended primers by separating the samples to single nucleotide resolution.  
Apo3G did not show an easily detectable premature stop band indicating to us that there was 
little deamination (Figure 3.8 A, Apo3G). 
To quantify the results of the deamination, we chose to sequence the non-transcribed 
strand using a ddG reaction.  This was necessary because the ddG reaction was able to 
demonstrate if both of the cytosines in the 5'CTC motif by Apo3H were deaminated (Figure 3.8 
A, Apo3H compare ddA and ddG lanes).  In the Apo3H sequencing reaction, a stop band in the 
ddG lane would arise when the polymerase was required to incorporate its first cytosine into the 
extended DNA strand.  Here the observed bypass band (Figure 3.8 A, Apo3H ddG arrow) is 
caused by sequencing pass through where the cytosine template has been changed to a U (Figure 
3.8 A, Apo3H ddG). Apo3H demonstrated 3 stop bands due to its sequence preference (5'CTC); 
the first represents the un-deaminated templates, the second represents the single deaminated 
substrates, and the third represents the deaminated substrates where both cytosines were 
deaminated (Figure 3.8 A, Apo3H ddG).  Activity recorded for Apo3H was the sum of both of 
the pass through stop bands.  In the ddG lanes for AID and Apo3A, we observed a strong stop 
band downstream of the deamination motif indicating that the target cytosine had been converted 
to uracil since sequencing reaction had passed through (Figure 3.8 A, AID and Apo3A ddG).  For 
Apo3G, the stop bands observed were only 1 nt apart because sequencing stops at the first C and 
Apo3G requires a CCC motif (Figure 3.8).  Apo3G rarely deaminates more than one C in the 
CCC motif without an extended incubation time (data not shown). 
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Apo3A and AID were able to deaminate 50.0% and 48.4% respectively of all cytosines 
after 30 min (Figure 3.8 B).  Apo3G was not able to catalyze deaminations efficiently (Figure 3.8 
B, 7.4%, 30 min) in this system.  Apo3H was able to catalyze the deamination of 62.5% of 
cytosine motifs after 30 min indicating that it was highly active in this system (Figure 3.8 B).  
We compared the rate of reaction between Apo3H, AID, and Apo3A. Apo3H had the highest 
rate of reaction at 7% (cytosines deaminated)/min (Figure 3.8 B).  AID and Apo3A had rates of 
5%/min and 2.5%/min respectively (Figure 3.8 B). 
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Figure 3.8 Deamination of dsDNA undergoing transcription by Apo3A, Apo3H, AID, and 
Apo3G.  A, The non-transcribed strand of a dsDNA substrate that underwent T7 RNA 
polymerase-mediated transcription in the presence of AID, Apo3A, Apo3H, and Apo3G was 
sequenced using the primer elongation dideoxynucleotide termination assay.  The sequence is 
indicated to the left of each gel.  The U/C label indicates the cytosine embedded within the 
preferred deamination motif for AID, Apo3A, Apo3H and Apo3G.  When the C is deaminated to 
U, a stop band will be present at that position in the ddA lane.  In the ddG lane, the presence of a 
U allows synthesis to bypass the U/C site and the next C in the sequence will have a stop band 
(arrow) with an intensity that is proportional to the amount of C deamination.  DNA only 
indicates that no deaminase was present and shows the expected stop bands in the absence of 
deamination.  B, time course of deamination of dsDNA during T7 RNA polymerase-mediated 
transcription.  Error bars represent the standard deviation calculated from three independent 
experiments. Adapted from Love et al. 2012. 
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4.1 Biochemical determinants for successful restriction of HIV 
Restriction of HIV by Apo3 enzymes requires that they interact with the viral genome 
and induce mutagenesis in a deamination dependent manner (Berger et al., 2011; Yu et al., 
2004).  In the case of Apo3G, it is packaged into the Δvif HIV virions and upon entering the 
target cell is able to induce considerable numbers of G to A mutations in the nascent provirus 
(Harris et al., 2003; Mangeat et al., 2003; Sheehy et al., 2002; Zhang et al., 2003).  Apo3A in the 
target cell can act as a post-entry block and has been demonstrated to cause inhibition of HIV 
infection in monocytes, macrophages, and myeloid lineage cells (Berger et al., 2011; Koning et 
al., 2011; Peng et al., 2007).  There is however, the potential for the Apo3 enzymes to catalyze 
sublethal numbers of deaminations that may lead to evolution of the virus (Jern et al., 2009; Kim 
et al., 2010; Mulder et al., 2008; Pillai et al., 2008; Sadler et al., 2010).  In this research, we 
applied a model HIV replication system that utilized specific nucleic acid structures that mimic 
HIV replication in vivo as well as physiologically relevant concentrations of proteins (Briggs et 
al., 2004; Coffin, 1997; Xu et al., 2007; Zhu et al., 2003) to assess how well Apo3A, Apo3H and 
Apo3G can induce deaminations (Figures 2.1 and 3.5-7).  We also used synthetic ssDNA 
substrates to determine the mechanism by which these enzymes scan ssDNA (Figure 3.1 and 
3.2).  We determined that the characteristic deamination motif preferred by Apo3A, Apo3G, and 
Apo3H on ssDNA were retained in a dynamic model HIV replication system, but processivity, or 
lack of, could not be easily discerned (Figure 3.5 and 3.6).  Apo3G is highly processive and uses 
a dual sliding and jumping scanning mode (Chelico et al., 2006). The balance between sliding 
and jumping was considered crucial for its ability to cause large numbers of mutations (Feng and 
Chelico, 2011), but it was not known if processivity per se was required for inducing 
mutagenesis during reverse transcription since a non-processive mutant Apo3G has not been 
developed.  We found that while Apo3G was able to induce large numbers of mutations, Apo3A, 
without being processive, was also able to catalyze many mutations per clone (Figure 3.6).  
Fewer mutations for Apo3A were found in regions that were single stranded for a small amount 
of time, suggesting that processivity does play a role, but a seemingly minor role (Figure 3.5).  
Apo3G was able to generate clones with larger numbers of mutations at a greater frequency than 
Apo3A, but clones generated by Apo3A were more diverse with less shared mutations than 
Apo3G (Figure 3.6).  Apo3H appeared to be intermediate between Apo3G and Apo3A in terms 
of the number of mutations per clone and the frequency of highly mutated clones.  The data 
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appear to indicate that this may be because Apo3H uses sliding (85%) more than jumping (15%) 
(Figure 3.2 and discussion in section 3.2.2).  Apo3G uses jumping approximately 60% of the 
time and slides 40% of the time and this more balanced ratio was found important to have 
efficient local scanning and reaching many areas along the (-)DNA (Feng and Chelico, 2011). 
The most striking result was that no matter how many mutations were induced by Apo3A 
or Apo3H, their potential for inactivating the HIV protease was much lower than Apo3G due to 
the propensity of Apo3A and Apo3H to induce missense mutations that change an amino acid 
within a conserved group (i.e. similar charge or size) as opposed to Apo3G which usually causes 
missense mutations outside of a conserved amino acid group (Table 3.2).  Apo3G has a 
preference for the 5'CCC motif while Apo3A and Apo3H have a preference for the 5'TC motif 
and this resulted in a different codon change potential.  This resulted in a substantially different 
amino acid substitution profile in the HIV protease gene.  In the sequence that we used, the 
active site of the prot gene of HIV-1, we observed that the sequence motif preference of Apo3G 
most often results in amino acid changes compared to Apo3A and Apo3H (Table 3.2).  In fact, 
silent mutations were only observed with enzymes that prefer the 5'TC motif (Table 3.2).  Clones 
generated by Apo3A and Apo3H most often coded for an active protease because of the 
frequency of non-inactivating mutations or silent mutations (Figure 3.7 and Table 3.2). 
There appear to be two key differences in the 5'CCC and 5'NTC deamination motifs that 
account for our observations. The 5'CC motif is found in codons for Gly (Table 3.1, 5'GGN). 
The deamination would occur on the complementary DNA strand in the context of 5'CCN, 
5'CCC, and rarely 5'CCN (underlined C is deaminated) or any combination (Table 3.1). These 
changes mostly resulted in mutation of the Gly to a charged amino acid (Table 3.1; Arg, Glu, or 
Lys) which is a non-conservative change that has a high chance to cause gene inactivation, 
especially if the change takes place near the enzyme active site (Betts and Russel, 2003; Loeb et 
al., 1989). Further, it has been suggested that Apo3G can result in a high frequency of stop 
codons being introduced into the HIV coding sequence because the only codon for Trp, 5'TGG is 
a minimal Apo3G deamination motif in the (-)DNA strand (5'CCA) (Yu et al., 2004). 
Deamination of the second C would result in the coding sequence being changed to 5'TAG. In 
our prot sequence there is one Trp codon and Apo3G did induce mutagenesis to form a stop 
codon 16% of the time (Table 3.2). The 5'TC sequence has neither of these features. The 5'TC 
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sequence most often occurs in the codon for Asp and the deamination-induced mutation changes 
it to an Asn (Table 3.2). This change from an acidic amino acid (Asp) to its amide (Asn) is a 
conservative change at position D35 and D25 that maintains the activity of the protease (Betts 
and Russel, 2003; Loeb et al., 1989). The only other amino acid change Apo3A induced at a high 
level is the Met to Ile mutation (Table 3.2), which is also considered to be a conservative change 
(Betts and Russel, 2003; Loeb et al., 1989). Apo3A could cause a stop codon to be formed at 
position 42 in 4% of clones (Table 3.2), but this is an off-target site, i.e., not 5'TC. However, the 
Trp codon occurred with a surrounding sequence context of 5'A TGG A, which would read as 
5'T CCA T in the (-)DNA, and enabled Apo3A to induce mutagenesis of the codon to 5'TGA in 
8% of clones (Table 3.2).  The resistance inducing Met to Ile mutation was found in 20% of 
Apo3H mutated clones (Table 3.2).  This suggests that the 5'TC motif is inherently less likely to 
cause gene inactivation, as demonstrated by our data on Apo3A- and Apo3H-induced 
mutagenesis of HIV-1 protease (Table 3.2, Figure 3.7).  One important note is that Apo3H did 
induce nonsense mutations in a total of 36% of clones compared to Apo3G with 16% but that did 
not carry forward to a greater total protease inactivation than Apo3G (Table 3.2, Figure 3.7) .  
That the deamination motif has a high likelihood to be located in a certain codon allows us to 
extrapolate our data from the prot region (Table 3.2) to infer what would occur during replication 
of HIV. The data (Table 3.2, Figure 3.7) suggest that Apo3A and Apo3H would be less effective 
at restricting HIV replication and rather contribute to HIV evolution and drug resistance (Table 
3.2, Figure 3.7). It is particularly dangerous that Apo3A is able to induce such a large number of 
drug resistant mutations at M46I (Table 3.2, 52% of clones) and D30N (Table 3.2, 24% of 
clones). This is because even if Apo3A were to mutationally inactivate an HIV provirus it would 
likely harbour these drug resistant mutations and upon integration could act as a repository for 
viral recombination, as has been demonstrated for Apo3G (Mulder et al., 2008; Smyth et al., 
2012). A recent analysis of how Apo3A restricts HIV replication suggests that Apo3A, in 
addition to or as a result of deaminating (-)DNA, decreases viral transcripts (Berger et al., 2011). 
This must be an evolutionarily favoured use of Apo3A, in which the provirus formation is 
blocked and therefore integration is avoided to suppress possible Apo3A-induced viral evolution. 
Taken together these results indicate that sequence deamination preference is a higher 
value determinant of Apo3-mediated HIV-1 inhibition than processivity.  It appears that Apo3A 
and Apo3H might result in HIV evolution rather than its inactivation (Table 3.2 and 3.7).  This 
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may be why Apo3A has a specialized role to inhibit HIV in myeloid cells where it is thought that 
Apo3A deaminations result in HIV proviral degradation through DNA repair enzyme processing 
rather than functional inactivation (Berger et al., 2011).  If this was not the role for Apo3H it 
could explain how it was ineffective, leading to its inactivation through evolution. 
4.2 The potential of Apo3A and Apo3H to deaminate nuclear DNA 
Apo3A and Apo3H can localize to the nucleus where they can come into contact with 
nuclear DNA (Chen et al., 2006; OhAinle et al., 2008).  DNA is only vulnerable to deamination 
by Apo3 enzymes when it is single stranded, so nuclear DNA is protected when it is not being 
replicated or transcribed.  AID has been demonstrated to cause large amounts of mutagenesis of 
nuclear DNA in recent reports (Hasham et al., 2010; Liu et al., 2008; Robbiani et al., 2008).  
AID functions to deaminate nuclear DNA to initiate somatic hypermutation when the antibody 
genes are being transcribed (Di Noia and Neuberger, 2007; Peled et al., 2008). 
Apo3A has been shown to cause cell cycle arrest due to large amounts of nuclear DNA 
damage, but the mechanism is unknown although it was suggested to be occurring during 
replication (Landry et al., 2011).  Apo3A has also been shown to cause deamination mediated 
cell death when its interaction partner TRIB3 is silenced, suggesting that human cells exert 
specific control over Apo3A deamination activity (Aynaud et al., 2012).  Here we showed that 
Apo3A can deaminate DNA during transcription.  This could be a mechanism, in addition to 
accessing ssDNA during nuclear DNA replication by which nuclear DNA is deaminated.  
Overall it appears there is a genomic cost for a mutationally based retroviral restriction system. 
We hypothesized that Apo3H has been evolutionarily destabilized because it was causing 
deaminations to the host cell or became ineffective at restricting HIV or other retroelements.  
Although our data suggests Apo3H is not as effective as Apo3G in restriction of HIV (Table 3.2 
and Figure 3.5-7), OhAinle et al. (2008) suggest that Apo3H has been required for element 
restriction in the recent past due to evidence of positive selection.  The alternative hypothesis 
appears to be better supported since for Hap I, II and VII, a correlation can be made between the 
degree of nuclear localization (Hap I > Hap VII > Hap II) and their instability in the cell (Wang 
et al., 2011; Zhen et al., 2012).  Li and Emerman (2011) postulated that a critical residue for 
stability, Arg 105, mediates an interaction with a cellular protein which could sequester Apo3H 
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in the cytoplasm, suggesting that nuclear localization is detrimental.  In agreement with these 
hypotheses we tested the potential of transcription as a target for Apo3H mediated deamination 
and found that indeed Apo3H was highly effective in this regard (Figure 3.2 and Table 3.1).  
Apo3H was found to catalyze deamination of DNA undergoing transcription with at least a 1.4-
fold higher rate a higher rate than Apo3A, Apo3G, and AID (Figure 3.8).  The primary target for 
AID activity is ssDNA exposed during gene transcription (Bachl et al., 2001; Pham et al., 2003).  
We propose that Apo3H could be too effective in deaminating nuclear DNA that is temporarily 
single stranded.  Future cell-based experiments are necessary to determine the potential 
detrimental effects of high Apo3H expression (See Section 5.4).  But biochemical experiments 
suggest that Apo3H could be at least as detrimental to cellular DNA as AID.  Importantly AID 
has been suggested to be responsible for 60% of B cell lymphomas (Robbiani et al., 2008). 
While the activity for deaminating transcribed DNA was the highest for Apo3H, we did 
observe a relatively high activity for Apo3A as well (Figure 3.8).  We propose two possible 
explanations for sustained expression of Apo3A in cells coexisting with potential damage.  The 
first explanation is that since the activity of Apo3A is less than AID, DNA repair can easily 
correct the catalyzed uracils and DNA repair systems do not become saturated, despite the 
constant presence of Apo3A in the nucleus.  The second possible explanation is that a cellular 
mechanism controls Apo3A activity, similar to AID access to the nucleus being controlled by 
phosphorylation (Vuong et al., 2009). While this thesis was being written, there was a report 
published that identified the TRIB3 as able to attenuate Apo3A activity in the nucleus and 
protects genomic integrity (Aynaud et al., 2012).  When the TRIB3 protein was silenced the cells 
died as a result of hypermutation of their genomes.  The TRIB3 protein did not interact with 
Apo3H (Aynaud et al., 2012), suggesting that cells are missing a control that would suppress the 
activity of Apo3H.  This is in agreement with Li and Emerman (2011) that proposed the 
stabilizing Arg 105 residue in Apo3H haplotypes mediated an interaction with a cellular protein 
that re-routed Apo3H localization to the cytoplasm.  The Apo3H haplotypes without Arg 105 are 
primarily nuclear and have a short half life in cells (<30 min) (OhAinle et al., 2008). 
Since it was a recent event in evolution that Apo3H lost a nuclear export signal (OhAinle 
et al., 2008), by acquiring a premature stop codon, perhaps the most rapid way to deal with the 
acquired genomic instability was to cause the rapid degradation of Apo3H in cells.  The 
77 
 
identification of the proposed cellular partner allowing for prolonged Apo3H stability in cells (Li 
and Emerman, 2011) may shed more light on the evolution of Apo3H in humans and its main 
function in innate immunity. 
4.3 Conclusion 
The experiments performed here have demonstrated that there is a large amount of 
diversity between the Apo3 enzymes and specifically that Apo3G is not a truly representative of 
the rest of the APOBEC3 family.  The Apo3 enzymes were first identified by Apo3G’s ability to 
inhibit HIV and this narrowed the scope of experimentation and discovery surrounding these 
enzymes.  It is now becoming clear that mutagenesis has a role in the immune system both in the 
adaptive (AID – antibody maturation) and innate (Apo3 – restriction factors) branches.  The 
biochemical data presented here forms a strong platform to test these biochemically-based 
hypotheses in cell-based experiments.  
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5.1 Investigate the relationship between HIV-1 reverse transcriptase fidelity and Apo3 
Working with our model reverse transcription system proved to be a rewarding 
endeavour.  We attempted to use this assay to further study processivity by modifying the 
concentrations and reactions times.  The goal was to observe a 15% population mutation 
frequency (white colonies) by altering the Apo3 enzyme concentration.  This would mean that 
the large majority of clones had arisen from a single encounter with a single Apo3 enzyme. 
Although this would not represent the in vivo situation where Apo3 enzymes could have multiple 
encounters with viral (-)DNA, we thought it would allow us to further study differences in 
processivity. From its onset we thought it may be difficult because RT was able to cause around 
10% white colonies from inherent replication errors.  Once the conditions gave the desired 
amount of white colonies we sequenced the clones but expected to see mostly random RT-
catalyzed errors.  The sequences that were returned were unexpected with a greatly reduced 
number of random RT errors in the presence of the Apo3 enzyme than in its absence. This was 
confounding, but was repeatable many times and was found to occur in the presence of any of 
the Apo3 enzymes tested here.  It appears that the relationship between the Apo3 enzymes and 
HIV-1 RT is not one of constant odds, but one where Apo3 enzymes interacting with the  
(-)DNA may alter the kinetics of RT dNTP incorporation by slowing down the reaction due to 
steric hindrance (Webb, 2012).  This may allow for RT to spend more time in selecting the 
correct dNTP and result in more accurate replication.  If this hypothesis is true then potentially 
Apo3 enzymes could lead to positive evolution of the HIV-1 virus not just through sublethal 
numbers of mutations by deamination (Jern et al., 2009; Kim et al., 2010; Mulder et al., 2008; 
Pillai et al., 2008; Sadler et al., 2010), but by reducing the total number of mutations (including 
lethal) normally induced by RT. 
5.2 Determine level of deamination on the transcribed strand during active transcription 
When we performed the active transcription assay we only investigated the level of 
deamination on the non-transcribed strand.  We hypothesized that if any deamination was 
occurring it would be occurring away from the T7 polymerase, similar to AID (Pham et al., 
2003).  However, in order for double strand breaks to occur through DNA repair processing, 
which is the reason why Apo3A- or AID-mediated deaminations are detrimental, some 
deaminations are expected to occur on the transcribed strand.  
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5.3 Exploring processivity during active transcription 
The active transcription system that we used here was effective in showing differences 
between Apo3G, a double domain Apo3 enzyme, and the single domain Apo3 enzymes and AID 
(Figure 3.8).  The limitations of the current active transcription assay, compared to the standard 
deamination assay, are that we did not have a second cytosine motif to investigate any 
coordinated deamination potential as we demonstrated in the deamination assay (Section 3.1 and 
3.2).  We did observe more than one deamination with Apo3H due to having two cytosines in the 
sequence motif preference so it would likely be possible to create a synthetic DNA that 
possessed two cytosine motifs that could be used for determining if deaminations that occur 
during gene transcription are processive.  If two sequencing primers were used for the same 
DNA to quantify deamination at each motif separately, the experiment would be quantitative and 
feasible. 
5.4 Determine level of genomic editing induced by Apo3H in tissue culture 
The next step to develop our understanding of the level of nuclear DNA damage induced 
by Apo3H should be investigated in tissue culture.  First, we need to demonstrate that Apo3H 
can deaminate nuclear DNA as our results suggest (Figure 3.8).  We plan to use a 293T cell lines 
that has stable expression of an inhibitor of uracil-N glycosylase (Kaiser and Emerman, 2006). 
In the presence or absence of expression of Apo3H (Hap I and VII) we will determine the 
amount of uracil in nuclear DNA.  The detection techniques we plan to use is differential PCR.  
In this method, different denaturing temperatures are used.  If a genome has sustained many G to 
A mutations then the annealing temperature of the dsDNA is reduced and the PCR reaction can 
be successful with a lower denaturing temperature.  This method has been used to determine the 
level of Apo3A related editing of nuclear DNA (Suspene et al., 2011a).  
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Appendix Item 7.1 Mutation possibilities as revealed in context of HIV reverse 
transcription.  Deaminations occur on the non-coding strand.  Codons highlighted in red 
indicate no change to amino acid, green indicates change in conservative amino acid group, 
white indicates same conservative amino acid group (Loeb et al., 1989).  Star indicated preferred 
codon usage pattern for HIV (Stephens and Waelbroeck, 1999). 
5'TC motif within codon   No possible deamination 
Aspartic Acid  *GAU  →  AAU  Asparagine  Phenylalanine  UUU, UUC 
Aspartic Acid  GAC  →  AAC  Asparagine  Isoleucine  AUU, AUC 
Glutamic Acid  *GAA  →  AAA  Lysine  Proline  CCU, CCC, CCA 
Glutamic Acid  GAG  →  AAG  Lysine  Tyrosine  UAU, UAC 
Stop (Opal)  UGA  →  UAA  Stop (Ochre)  Stop (Ochre)  UAA 
Arginine  CGA  →  CAA  Glutamine  Histidine  CAU, CAC 
Arginine  *AGA  →  AAA  Lysine  Asparagine  AAU, AAC 
Glycine  *GGA  →  GAA  Glutamic Acid 
5'CC motif within codon 
Tryptophan  *UGG  →  UAG  Stop (Amber) 
Arginine  CGG  →  CAG  Glutamine 
Arginine  AGG  →  AAG  Lysine 
Glycine  GGU  →  AGU  Serine 
Glycine  GGC  →  AGC  Serine 
Glycine  *GGA  →  AGA  Arginine 
Glycine  GGG  →  AGG  Arginine 
5'(T/C) preceding codon 
Leucine  UUG(A/G)  →  UUA  Leucine 
Leucine  CUG(A/G)  →  CUA  Leucine 
Methionine  AUG(A/G)  →  AUA  Isoleucine 
Valine  GUG(A/G)  →  GUA  Valine 
Serine  UCG(A/G)  →  UCA  Serine 
Proline  CCG(A/G)  →  CCA  Proline 
Threonine  ACG(A/G)  →  ACA  Threonine 
Alanine  GCG(A/G)  →  GCA  Alanine 
Stop (Amber)  UAG(A/G)  →  UAA  Stop (Ochre) 
Glutamine  CAG(A/G)  →  CAA  Glutamine 
Lysine  AAG(A/G)  →  AAA  Lysine 
Glutamic acid  GAG(A/G)  →  GAA  Glutamic acid 
Tryptophan  UGG(A/G)  →  UGA  Stop (Opal) 
Arginine  CGG(A/G)  →  CGA  Arginine 
Arginine  AGG(A/G)  →  AGA  Arginine 
Glycine  GGG(A/G)  →  GGA  Glycine 
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Appendix Item 7.2 Calculations used in determination of processivity factor 
DEFINING VARIABLES 
5’ deamination 
(5’) = (5’ deamination band intensity)/(total band intensities) 
3’ deamination 
(3’) = (3’ deamination band intensity)/(total band intensities) 
Actual correlated deamination 
(5’&3’) = (double deamination band intensity)/(total band intensities) 
Total 5’ deamination 
(5’)C = (5’ & 3’) + (5’) 
Total 3’ deamination 
(3’)C = (5’ & 3’) + (3’) 
 
 
Expected Value of correlated deamination = (5’)C x (3’)C 
 
 
Processivity Factor = Actual/Expected = (5’ & 3’)/[(5’)C x (3’)C] 
 
 
